



**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Consolidated Financial Statements

June 30, 2015 and 2014

and

Audit of Federal Awards Performed
in Accordance with U.S. Office of
Management and Budget Circular A-133

June 30, 2015

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Table of Contents

	Page(s)
Independent Auditors' Report	1 – 2
Consolidated Balance Sheets	3
Consolidated Statements of Activity	4 – 5
Consolidated Statements of Cash Flows	6
Statements of Functional Expenses	7
Notes to Consolidated Financial Statements	8 – 30
Independent Auditors' Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	31 – 32
Independent Auditors' Report on Compliance with Requirements That Could Have a Direct and Material Effect on Each Major Program and on Internal Control over Compliance in Accordance with OMB Circular A-133	33 – 35
Schedule of Expenditures of Federal Awards	36 – 45
Notes to Schedule of Expenditures of Federal Awards	46 – 53
Schedule of Findings and Questioned Costs	54



KPMG LLP
Suite 2900
1918 Eighth Avenue
Seattle, WA 98101

Independent Auditors' Report

The Board of Trustees
Fred Hutchinson Cancer Research Center:

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of Fred Hutchinson Cancer Research Center (the Center), which comprise the consolidated balance sheets as of June 30, 2015 and 2014, and the related consolidated statements of activities statement of functional expense, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Fred Hutchinson Cancer Research Center as of June 30, 2015 and 2014, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 22, 2015 on our consideration of the Center's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Center's internal control over financial reporting and compliance.

KPMG LLP

October 22, 2015

FRED HUTCHINSON CANCER RESEARCH CENTER

Consolidated Statements of Financial Position

June 30, 2015 and 2014

(In thousands)

Assets	2015	2014
Assets:		
Cash and cash equivalents	\$ 32,034	4,016
Limited use investments	11,125	20,907
Grants and contracts receivable, net	18,905	21,594
Notes and pledges receivable, net	4,393	4,794
Other receivables, net	13,899	12,183
Investments	340,416	163,595
Trustee-held funds	10,940	10,929
Land, buildings, and equipment, net of accumulated depreciation of \$326,983 and \$309,062, respectively	365,427	366,904
Beneficial interest in perpetual trusts	27,677	28,644
Beneficial interest in assets of SCCA	102,497	96,584
Other assets	25,995	8,542
	<hr/>	<hr/>
Total assets	\$ 953,308	738,692
	<hr/> <hr/>	<hr/> <hr/>
Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued liabilities	\$ 11,644	12,480
Accrued payroll and related costs	17,696	16,352
Deferred revenue	51,949	40,774
Long-term debt	353,371	358,542
Deferred credit on cash flow hedges	28,684	28,786
	<hr/>	<hr/>
Total liabilities	463,344	456,934
	<hr/>	<hr/>
Net assets:		
Unrestricted	364,402	173,015
Temporarily restricted	65,683	50,607
Permanently restricted	59,879	58,136
	<hr/>	<hr/>
Total net assets	489,964	281,758
	<hr/>	<hr/>
Total liabilities and net assets	\$ 953,308	738,692
	<hr/> <hr/>	<hr/> <hr/>

See accompanying notes to consolidated financial statements.

FRED HUTCHINSON CANCER RESEARCH CENTER

Consolidated Statement of Activities

Year ended June 30, 2015

(In thousands)

	2015			
	Unrestricted	Temporarily restricted	Permanently restricted	Total
Revenues and other support:				
Research grants and contracts	\$ 321,476	—	—	321,476
Contributions, net of cost of special events of \$2,220	19,616	26,500	2,662	48,778
Investment income and realized gains and losses	53,692	1,006	33	54,731
Royalty income	6,887	—	—	6,887
Clinical service fee revenue	16,265	—	—	16,265
Other income	38,150	—	—	38,150
Net assets released from restrictions	10,655	(10,655)	—	—
Total revenues	<u>466,741</u>	<u>16,851</u>	<u>2,695</u>	<u>486,287</u>
Expenses:				
Program services research	337,789	—	—	337,789
Management and general	88,372	—	—	88,372
Fund-raising	8,080	—	—	8,080
Total expenses	<u>434,241</u>	<u>—</u>	<u>—</u>	<u>434,241</u>
Change in net assets from operations	<u>32,500</u>	<u>16,851</u>	<u>2,695</u>	<u>52,046</u>
Other changes in net assets:				
Change in net unrealized fair value of investments	158,629	(1,775)	14	156,868
Change in net foreign currency translation	276	—	—	276
Change in value of split-interest agreements	(120)	—	(966)	(1,086)
Change in net unrealized fair value of swap instruments	102	—	—	102
Total other changes in net assets	<u>158,887</u>	<u>(1,775)</u>	<u>(952)</u>	<u>156,160</u>
Total increase in net assets	191,387	15,076	1,743	208,206
Net assets balance at beginning of year	<u>173,015</u>	<u>50,607</u>	<u>58,136</u>	<u>281,758</u>
Net assets balance at end of year	\$ <u><u>364,402</u></u>	\$ <u><u>65,683</u></u>	\$ <u><u>59,879</u></u>	\$ <u><u>489,964</u></u>

See accompanying notes to consolidated financial statements.

FRED HUTCHINSON CANCER RESEARCH CENTER

Consolidated Statement of Activities

Year ended June 30, 2014

(In thousands)

	2014			
	Unrestricted	Temporarily restricted	Permanently restricted	Total
Revenues and other support:				
Research grants and contracts	\$ 314,083	—	—	314,083
Contributions, net of cost of special events of \$1,692	16,208	21,384	388	37,980
Investment income and realized gains and losses	29,452	1,987	—	31,439
Royalty income	7,284	—	—	7,284
Clinical service fee revenue	15,180	—	—	15,180
Other income	30,584	—	—	30,584
Net assets released from restrictions	8,652	(8,652)	—	—
Total revenues	<u>421,443</u>	<u>14,719</u>	<u>388</u>	<u>436,550</u>
Expenses:				
Program services research	320,511	—	—	320,511
Management and general	85,538	—	—	85,538
Fund-raising	8,257	—	—	8,257
Total expenses	<u>414,306</u>	<u>—</u>	<u>—</u>	<u>414,306</u>
Change in net assets from operations	<u>7,137</u>	<u>14,719</u>	<u>388</u>	<u>22,244</u>
Other changes in net assets:				
Change in net unrealized fair value of investments	18,337	2,890	—	21,227
Change in net foreign currency translation	(162)	—	—	(162)
Change in value of split-interest agreements	(171)	72	2,246	2,147
Change in net unrealized fair value of swap instruments	1,449	—	—	1,449
Total other changes in net assets	<u>19,453</u>	<u>2,962</u>	<u>2,246</u>	<u>24,661</u>
Total increase in net assets	<u>26,590</u>	<u>17,681</u>	<u>2,634</u>	<u>46,905</u>
Net assets balance at beginning of year	<u>146,425</u>	<u>32,926</u>	<u>55,502</u>	<u>234,853</u>
Net assets balance at end of year	\$ <u><u>173,015</u></u>	<u><u>50,607</u></u>	<u><u>58,136</u></u>	<u><u>281,758</u></u>

See accompanying notes to consolidated financial statements.

FRED HUTCHINSON CANCER RESEARCH CENTER

Consolidated Statements of Cash Flows

Years ended June 30, 2015 and 2014

(In thousands)

	<u>2015</u>	<u>2014</u>
Cash flows from operating activities:		
Change in net assets	\$ 208,206	46,905
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Depreciation and amortization	23,977	24,710
Noncash deferred revenue	(815)	(715)
Equity in earnings of SCCA	(13,530)	(11,746)
Change in net unrealized gains in fair value of investments	(156,868)	(21,227)
Change in value of split-interest agreements	1,086	(2,208)
Change in fair value of swap instruments	(102)	(1,449)
Net realized gains on investments	(39,075)	(17,688)
Noncash contributions	(12,935)	(13,396)
Permanently restricted contributions	(2,662)	(388)
Changes in assets and liabilities:		
Grants and contracts receivable	2,689	(1,807)
Notes and pledges receivable	401	(1,310)
Other receivables	(1,629)	7,856
Prepaid expenses and deposits	(771)	437
Accounts payable and accrued liabilities	(746)	(1,627)
Accrued payroll and related costs	1,344	(6,263)
Deferred grant and contract revenue	11,395	5,553
Net cash provided by operating activities	<u>19,965</u>	<u>5,637</u>
Cash flows from investing activities:		
Additions to land, buildings, equipment, and rental property	(30,532)	(25,619)
Purchase of investments	(85,549)	(42,707)
Sale of investments	113,540	40,096
Change in trustee-held funds	(11)	2,106
Net cash used in investing activities	<u>(2,552)</u>	<u>(26,124)</u>
Cash flows from financing activities:		
Proceeds from new debt	4,435	—
Additions to deferred financing costs	(349)	—
Repayment of debt	(9,609)	(4,931)
Contributions restricted for long-term investment	15,597	13,784
Net cash provided by financing activities	<u>10,074</u>	<u>8,853</u>
Change in foreign currency translation	<u>531</u>	<u>389</u>
Net increase (decrease) in cash and cash equivalents	28,018	(11,245)
Cash and cash equivalents at beginning of year	<u>4,016</u>	<u>15,261</u>
Cash and cash equivalents at end of year	\$ <u>32,034</u>	\$ <u>4,016</u>
Supplemental disclosure of cash flow information:		
Interest paid	\$ 17,962	18,527
Capital expenditures in accounts payable	513	365

See accompanying notes to consolidated financial statements.

FRED HUTCHINSON CANCER RESEARCH CENTER

Consolidated Statements of Functional Expenses

Years ended June 30, 2015 and 2014

(In thousands)

		Program services research	Management and general	Fundraising	Total
		<u> </u>	<u> </u>	<u> </u>	<u> </u>
2015:					
Salaries and wages	\$	150,479	38,887	4,270	193,636
Employee benefits		37,614	9,247	1,041	47,902
Subawards		61,645	53	—	61,698
Purchased services		10,791	14,882	761	26,434
Supplies		23,259	2,724	62	26,045
Other		14,836	6,989	1,911	23,736
Rent, utilities, and maintenance		3,794	9,046	35	12,875
Interest and amortization		16,353	1,817	—	18,170
Depreciation		19,018	4,727	—	23,745
		<u> </u>	<u> </u>	<u> </u>	<u> </u>
Total June 30, 2015	\$	<u>337,789</u>	<u>88,372</u>	<u>8,080</u>	<u>434,241</u>
2014:					
Salaries and wages	\$	139,700	37,916	4,647	182,263
Employee benefits		36,983	8,041	1,169	46,193
Subawards		62,194	—	—	62,194
Purchased services		10,265	13,658	962	24,885
Supplies		21,147	2,390	99	23,636
Other		10,523	6,553	1,311	18,387
Rent, utilities, and maintenance		3,209	10,246	69	13,524
Interest and amortization		16,798	1,867	—	18,665
Depreciation		19,692	4,867	—	24,559
		<u> </u>	<u> </u>	<u> </u>	<u> </u>
Total June 30, 2014	\$	<u>320,511</u>	<u>85,538</u>	<u>8,257</u>	<u>414,306</u>

See accompanying notes to consolidated financial statements.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

(1) Organization

Fred Hutchinson Cancer Research Center (the Center), a Washington not-for-profit corporation, is organized and operated exclusively for charitable, scientific, and educational purposes, within the meaning of Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, including without limitation (i) eliminating cancer as a cause of human suffering and death; (ii) conducting investigations into the nature and causes of cancer and related medical and public health problems; (iii) investigating methods of prevention and treatment of cancer and related diseases; (iv) conducting education in all phases of cancer research; (v) performing research in all aspects of biomedical science that have a relationship to cancer; (vi) disseminating knowledge acquired pursuant to the foregoing activities; and (vii) maintaining facilities for cancer and related biomedical research. The Center is designated by the National Cancer Institute as a comprehensive cancer research center.

Controlled Affiliates of the Center

Hutchinson Centre Research Institute in Uganda Limited (HCRIU), is a Uganda not-for-profit corporation. It is organized and operated for the purpose of researching, detecting, treating and preventing infection-related cancers in Uganda and throughout the world. The Center is the sole member of HCRIU. The income and property of HCRIU is restricted to be used in meeting its organizational objectives. The net assets of HCRIU of \$(2,201) and \$(1,159) as of June 30, 2015 and 2014, respectively, are not considered pledged assets under debt covenants.

Hutchinson Centre Research Institute of South Africa (HCRISA) is a South Africa not-for-profit corporation. It is organized and operated for the purpose of promoting and conducting clinical, laboratory and other research aimed at the prevention, early detection, diagnosis, and treatment of HIV/AIDS, Tuberculosis and other infectious diseases and cancer in South Africa and throughout the world. The Center is the sole member of HCRISA. The income and property of HCRISA is restricted to be used in meeting its organizational objectives. The net assets of HCRISA of \$943 and \$(162) as of June 30, 2015 and 2014, respectively, are not considered pledged assets under debt covenants.

Seattle Vaccine Research Fund (SVRF), a Washington State not-for-profit corporation, is exempt from federal taxes under Section 501(c)(3). It is operated for the purpose of providing anti retrovirals to eligible participants of HIV Trials Network. The net assets of SVRF of \$443 and \$441 as of June 30, 2015 and 2014, respectively, are not considered pledged assets under debt covenants.

(2) Summary of Significant Accounting Policies

(a) *Basis of Presentation*

The consolidated financial statements include the accounts of the Center and its controlled affiliates, collectively referred to as the Center. All significant intracompany balances and transactions between the Center and its controlled affiliates have been eliminated in consolidation.

(b) *Use of Estimates*

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(c) Cash and Cash Equivalents

Included in cash and cash equivalents are cash equivalents of approximately \$310 and \$314 as of June 30, 2015 and 2014, respectively, which are invested in money market funds and highly liquid debt instruments with original maturities of three months or less.

The Center maintains cash and cash equivalents on deposit at financial institutions, which at times exceed the limits insured by the Federal Deposit Insurance Corporation. This exposes the Center to potential risk of loss in the event that the financial institution becomes insolvent.

(d) Limited Use Investments

Limited use investments include designated unrestricted financial assets set aside by management for future capital and program purposes.

(e) Investments

Investments, including board-designated investments and other restricted investments, carried at fair value include cash and cash equivalents, equity securities, debt securities, and alternative investments.

(f) Trustee Held Funds

The components of trustee-held funds and the purposes for which they are being held as of June 30 are as follows:

	<u>2015</u>	<u>2014</u>
Trustee-held funds:		
U.S. government and agency obligations	\$ 10,940	10,929
	<u>\$ 10,940</u>	<u>10,929</u>
Purpose for which funds are held:		
Debt service reserve funds	\$ 10,940	10,929
	<u>\$ 10,940</u>	<u>10,929</u>

(g) Land, Buildings, and Equipment

Land, buildings, and equipment acquisitions are recorded at cost. Depreciation is provided over the estimated useful life of each class of depreciable asset and is computed using the straight-line method. Interest costs incurred on borrowed funds during the period of construction of capital assets are capitalized as a component of the cost of acquiring those assets. Improvements and replacements of land, buildings, and equipment are capitalized; maintenance and repairs costs are expensed.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360, *Property, Plant, and Equipment*, long-lived assets, such as property, plant, and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the long-lived asset may not be recoverable.

The Center receives reimbursement for a portion of its property, plant, and equipment through direct and indirect cost reimbursement primarily from the federal government in connection with federal grants.

(h) *Beneficial Interest in Assets of SCCA*

The Center accounts for its 33% ownership interest in Seattle Cancer Care Alliance (SCCA) using the equity method of accounting, as further discussed in note 14.

(i) *Deferred Financing Costs*

Financing costs incurred in connection with long-term obligations are deferred and amortized over the term of the credit enhancement facility for variable rate debt or the term of the debt using the effective interest method for fixed rate debt.

(j) *Deferred Grant and Contract Revenue and Research Grants and Contracts Receivable*

The balance in deferred revenue, on the accompanying statement of financial position, represents grant and contract funds received for services to be performed by the Center, which have not yet been expended under terms of the grant and contract agreements and which do not meet the criteria for reporting as contributions. The Center recognizes these amounts as revenue as such funds are expended. The Center also includes certain construction grants from the federal government as deferred revenue, which are recognized as revenue at the same rate as depreciation expense.

The balance in grants and contracts receivable, as reflected on the accompanying statement of financial position, represents expenditures made in accordance with the terms of provisions of the grants and contracts not yet reimbursed by cash.

(k) *Donor-Restricted Gifts*

Unconditional promises to give cash and other assets to the Center are reported at fair value at the date the promise is received. Conditional promises to give and intentions to give are reported at fair value at the date the gift is received or when the conditions are met. The gifts are reported as either temporarily or permanently restricted support if they are received with donor stipulations that limit the use of the donated assets or contain a time restriction. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net assets are reclassified as unrestricted net assets and reported in the statements of activity as net assets released from restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are reported as unrestricted contributions in the accompanying financial statements.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

(l) *Perpetual Trusts and Charitable Remainder Trusts*

The Center is the beneficiary of irrevocable perpetual trusts and charitable remainder trusts for which the Center is not the trustee. These funds held in trust by others represent resources neither in the possession nor under the control of the Center and are administered by outside trustees. When the Center is notified of the existence of an irrevocable perpetual trust, the Center recognizes its beneficial interest in the outside trust at fair value as a contribution. The contribution is classified as an increase in permanently restricted net assets based on restrictions placed by the donor. The changes in the fair value of the irrevocable perpetual trusts are reflected as investment changes restricted by donors, in permanently restricted net assets on the statements of activity.

When the Center is notified of an irrevocable charitable remainder trust for which it is not the trustee, the Center recognizes its beneficial interest in the outside trust as a contribution at fair value, which is measured as the present value of the estimated expected future benefits to be received. The contribution is classified as an increase in temporarily restricted net assets based on restriction placed by the donor upon the Center's beneficial interest in the assets. Periodic adjustments recorded to the beneficial interest to reflect changes in the fair value, life expectancy, and discount rate are recognized based on information from outside trustees. Any charitable remainder trusts for which the Center is not the trustee are reflected as a receivable from trusts and are included in other receivables in the accompanying consolidated statements of financial position. These amounts as of June 30, 2015 and 2014 were \$1,404 and \$1,952, respectively.

(m) *Foreign Currency Translation and Transaction Gains and Losses*

The consolidated financial statements include foreign currency amounts attributable to foreign operations. The foreign currency amounts have been translated into U.S. dollars using year-end exchange rates for assets and liabilities, historical rates for net assets and average annual rates for revenues and expenditures.

HCRISA's general ledger is maintained in South Africa rand, and their financial statements are measured using the currency of the primary economic environment in which the entity operates, which is South Africa rand. Unrealized gains or losses arising from fluctuations in the year-end exchange rates are recorded as net asset adjustments from foreign currency translation, and gains or losses resulting from actual foreign exchange transactions are recorded in revenues and expenses in the consolidated statements of activities. The foreign currency translation amounts to gains of \$354 at June 30, 2015 and losses of \$139 at June 30, 2014.

In accordance with the ASC Topic 230, *Statement of Cash Flows*, cash flows from HCRISA's operations are calculated based on its local reporting currency and translated to U.S. dollars.

HCRIU's general ledger is maintained in U.S. dollars, and its financial statements are measured using the currency of the primary economic environment in which the entity operates, which is U.S. dollars. Unrealized gains or losses arising from fluctuations in the year-end exchange rates, and gains or losses resulting from actual foreign exchange transactions are recorded in revenues and expense. The foreign currency translation losses amount to \$78 and \$23 at June 30, 2015 and 2014, respectively.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

(n) *Temporarily and Permanently Restricted Net Assets*

Temporarily restricted net assets are those that have uses that have been limited by donors to a specific time period or purpose. The Center's temporarily restricted net assets are restricted to scientific research expenses and other program related expenses.

Permanently restricted net assets have been restricted by donors to be maintained by the Center in perpetuity. The Center's permanently restricted net assets consist of various endowment funds and the Center's interest in perpetual trusts. Income earned on permanently restricted funds is used for operations in accordance with the terms of each endowment fund and the Uniform Prudent Management of Institutional Funds Act (UPMIFA).

(o) *Statements of Activities*

The statements of activities describe the results of various financial events that are included in presenting the change in the Center's net assets. Contributions received by the Center may be either unrestricted, temporarily restricted, or permanently restricted. Investment income and realized gains and losses may be temporarily restricted based on donor intent or unrestricted. Research grant and contract revenue generated by the Center and related expenses incurred are unrestricted. Changes in asset values resulting from "mark-to-market" adjustments to record unrealized gains and losses are shown as Other Changes in Net Assets. A total increase or decrease in net assets for each net asset grouping is shown to roll forward the beginning of the year balance to the end of the year balance.

(p) *Federal Income Taxes*

The Center has obtained a determination letter from the Internal Revenue Service that it is exempt from federal income taxes under Section 501(c)(3), except for unrelated business income.

(3) *Due from Government Agencies*

The Center incurs facilities and administrative (F&A) costs to support its research activities. Research programs are charged for these costs through an F&A cost rate, which is applied to modified total direct research costs. Both direct and F&A costs are recovered by the Center from research programs supported by federal and other grant revenue.

The fixed federal F&A rate for grant and contract supported programs is determined by prospective negotiation with the Department of Health and Human Services (DHHS) based on an estimate of the costs that will be incurred during the period to which the rate applies. Any difference between the costs recovered through the fixed F&A cost rate and actual F&A costs incurred represents an estimated F&A settlement with the federal government, which will be included in future rates. No estimated settlement was recorded as of June 30, 2015 or 2014.

(4) *Investments*

Investments are carried at fair value and include cash and cash equivalents, equity securities, debt securities and alternative investments. Fair value is defined as the price that the Center would receive upon selling an asset in an orderly transaction to an independent buyer in the principal or most advantageous market of the

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

investment. FASB ASC 820-10-50, *Fair Value Measurement*, established a three-tier hierarchy to maximize the use of observable market data and minimize the use of unobservable inputs, and to establish classification of fair value measurements for disclosure purposes. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk. Inputs may be observable or unobservable. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability based upon market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available. The three-tier hierarchy is summarized below:

- Level 1 – Valuation inputs are quoted prices in active markets for identical investments. At June 30, 2015 and 2014, Level 1 measurements include primarily cash and cash equivalents, domestic and global equities, equity funds, and bond funds.
- Level 2 – Valuation inputs are quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. At June 30, 2015 and 2014, Level 2 measurements included fixed income and debt securities, such as U.S. government obligations, mortgage-backed securities, corporate bonds, municipal obligations, interest rate swaps, and certain hedged equity and real asset funds.
- Level 3 – Valuation inputs are derived from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect the Center's estimates of assumptions that market participants would use in pricing the asset or liability. Valuation techniques include use of discounted cash flow models and similar techniques. At June 30, 2015 and 2014, Level 3 securities included hedged equity funds, private equity and venture capital funds, privately held equities, beneficial interests in charitable trusts, and beneficial interests in perpetual trusts.

The level in the fair value hierarchy within which a fair value measurement in its entirety falls is based on the lowest level input that is significant to the fair value measurement in its entirety.

The fair value of alternative investments is reported based on information provided by the respective alternative investment funds' managers. The alternative investments classified in Levels 2 and 3 consist of shares or units in investment funds as opposed to direct interests in the fund's underlying holdings, which may be marketable. Because the net asset value reported by each fund is used as a practical expedient to estimate the fair value of the Center's interest therein, its classification in Level 2 or 3 is based on the Center's ability to redeem its interest at or near the statement of financial position date. If the interest can be redeemed in the near term, the investment is classified as Level 2. The classification in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment's underlying assets and liabilities.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

(a) ***Fair Value Calculation Methodology***

The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value:

Cash and Cash Equivalents – The carrying amount (cost) approximates fair value because of the short maturity of those instruments.

Investments and Trustee-Held Funds – Investments in equity and debt securities, trustee-held funds, beneficial interest in charitable remainder trusts and perpetual trusts are measured at fair value based on quoted market prices, if available, or estimated using quoted market prices for similar securities. Alternative investments are measured at fair value based on each fund's net asset value as a practical expedient. Other equity securities, which are shares held in a nonpublic entity, are measured at fair value based on management's valuation model. Management's model utilizes data and assumptions that are not observable to market participants.

Long-Term Debt – The carrying amount of long-term debt with variable interest rates approximates fair value because interest rates are adjusted either daily or weekly for the variable rate demand bonds. The carrying amount of the fixed rate debt is calculated based upon the net present value of the future cash outflows of the associated fixed rate debt discounted at the interest rates in effect as of June 30, 2014.

Cash Flow Hedges – The carrying amounts of the interest rate swaps are at estimated fair values based on the net present value of the associated variable cash flows, adjusted for the Center's and the respective counterparty's nonperformance risk.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

(b) Fair Value Hierarchy

The following tables present assets and liabilities that are measured at fair value on a recurring basis at June 30, 2015 and 2014:

	2015			
	June 30, 2015	Level 1	Level 2	Level 3
Investments:				
Cash and cash equivalents	\$ 23,143	23,143	—	—
Global equity securities and mutual funds	248,064	231,912	12,269	3,883
Governments, mortgage and corporate debt funds	26,654	10,931	15,583	140
Real estate funds	6,221	—	—	6,221
Directional hedge funds	34,389	—	9,245	25,144
Private equity and venture capital funds	3,673	—	—	3,673
Commodity investments and funds	8,169	2,550	5,619	—
Other equity securities	1,228	1,085	—	143
Total investments	<u>\$ 351,541</u>	<u>269,621</u>	<u>42,716</u>	<u>39,204</u>

	2015			
	June 30, 2015	Level 1	Level 2	Level 3
Other receivables:				
Beneficial interest in charitable remainder trusts	\$ 1,404	—	—	1,404
Beneficial interest in perpetual trusts	27,677	—	—	27,677
Trustee-held funds	10,940	9,083	1,857	—
Liabilities:				
Deferred credit on cash flow hedges	\$ (28,684)	—	(28,684)	—

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

	2014			
	June 30, 2014	Level 1	Level 2	Level 3
Investments:				
Cash and cash equivalents	\$ 30,887	30,887	—	—
Global equity securities and mutual funds	62,516	42,546	19,970	—
Governments, mortgage and corporate debt funds	15,522	5,637	9,814	71
Global real estate funds	8,614	341	8,273	—
Directional hedge securities	34,539	—	9,879	24,660
Private equity and venture capital funds	8,826	—	—	8,826
Real estate hedge funds	7,196	—	—	7,196
Other equity securities	15,440	364	—	15,076
Other real and personal property	721	—	—	721
Commodity index fund	241	—	241	—
Total investments	\$ <u>184,502</u>	<u>79,775</u>	<u>48,177</u>	<u>56,550</u>

	2014			
	June 30, 2014	Level 1	Level 2	Level 3
Other receivables:				
Beneficial interest in charitable remainder trusts	\$ 1,952	—	—	1,952
Beneficial interest in perpetual trusts	28,644	—	—	28,644
Trustee-held funds	10,929	—	10,929	—
Liabilities:				
Deferred credit on cash flow hedges	\$ (28,786)	—	(28,786)	—

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

The following tables presents the Center's activities for assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended June 30, 2015 and 2014:

	2015	2014
Beginning balance, July 1	\$ 87,146	71,724
Transfers out of Level 3	(16,732)	(15)
Net realized and unrealized gains	3,916	24,645
Purchases	8,041	4,623
Sales	(7,735)	(9,581)
Return of capital distribution	(6,351)	(4,250)
Ending balance, June 30	\$ 68,285	87,146

The Center held securities in Juno Therapeutics, Inc. (Juno) on June 30, 2014 that were categorized as Level 3. In fiscal 2015, Juno completed a public offering resulting in a \$16,011 transfer out of the Level 3 category for the year. Additionally, during fiscal 2015, exchange traded shares of Juno were sold at a realized gain of \$31,120. The increased value of the Center's unsold Juno shares, compared to when Juno was privately held on June 30, 2014, resulted in unrealized gains in fiscal 2015 of \$167,610.

The following table summarizes the Center's Level 3 investments by major category, as well as related strategy, liquidity, and funding commitment as of June 30:

	June 30, 2015	June 30, 2014	Redemption or liquidation	Days notice	Unfunded commitment
Directional hedge funds	\$ 25,144	24,660	Qtrly – Every 2 yrs	30 – 184	N/A
Limited partnerships:					
Venture capital funds	592	989	N/A (1)	N/A	N/A
Global equity securities	3,883	—	Monthly	30	N/A
Private equity funds	3,081	7,837	N/A (1)	N/A	(2)
Real estate funds	1,974	3,617	N/A (1)	N/A	(3)
Real estate funds	4,247	3,579	Quarterly	90	N/A
Corporate debt funds	140	71	Daily	One	N/A
Other equity securities	143	15,076	N/A (1)	N/A	N/A
Other real and personal property	—	721	N/A (1)	N/A	N/A
Total investments	\$ 39,204	56,550			

- (1) Not eligible for redemption
- (2) Unfunded Commitment of \$405 and \$409 as of June 30, 2015 and 2014, respectively
- (3) Unfunded Commitment of \$523 and \$671 as of June 30, 2015 and 2014, respectively

At June 30, 2015 and 2014, the Center had \$5,790 and \$28,240, respectively, in investments that are not readily marketable. These are investments for which liquidation is at the discretion of the fund

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

manager. These investments represent 2% and 15% of total investments and 1% and 10% of net assets at June 30, 2015 and 2014, respectively. These investment instruments may contain elements of both credit and market risk. Such risks include, but are not limited to, limited liquidity, absence of regulatory oversight, dependence upon key individuals, emphasis on speculative investments (both derivatives and nonmarketable investments), and nondisclosure of portfolio composition. Because of these risks, the recorded value for these investments may differ from the value that would have been used had a ready market for such investments existed. Such differences could be material.

The Center has funds invested in 31 limited partnerships and companies with ownership interests ranging from 0.32% to 4.16% at June 30, 2015 and 2014. In 2015, three of these partnerships were venture capital funds, four are private equity, eighteen are hedge funds, three are debt funds, and two are real estate funds.

The Center's restricted investments contain endowment funds with donor restrictions for a variety of purposes. The Center's board-designated investments include funds designated by the board of trustees to function as endowments. The board of trustees may also periodically remove designations on funds previously designated. As required by GAAP, net assets associated with endowment funds, including funds designated by the board of trustees to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

Components of investment income for the years ended June 30 are as follows:

	<u>2015</u>	<u>2014</u>
Interest	\$ 1,762	1,784
Dividends	1,193	1,221
Net realized gains	39,075	17,688
Equity in earnings of SCCA investment	13,530	11,728
	<u>55,560</u>	<u>32,421</u>
Less investment management fees	(829)	(982)
	<u>\$ 54,731</u>	<u>31,439</u>

(5) Endowments

(a) *Return Objectives and Risk Parameters*

The Center has adopted investment and spending policies for its endowment that will provide resources to programs supported by the endowment. The endowment includes donor-restricted funds as well as board-designated investments. Under this policy, as approved by the Center's board of trustees, the primary objective of the investment of the endowment is to provide a rate of total return, including all gains and losses, realized and unrealized, which exceeds the rate of inflation (as represented by the Consumer Price Index-All Urban Consumers) plus 5% over the long term. The Center defines the long term as five years and more. Consistent returns are to be emphasized over individual year results, although the possibility of loss in a given year cannot be ignored. The endowment should experience risk (volatility and variability of return) no greater than that of the market. The Center defines the

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

market as the portfolio's asset allocation policy applied to the Russell 3000 Index, the Morgan Stanley Capital Europe, Australia, Far East (EAFE) Index or its equivalent, and the iShares Barclays Aggregate Bond Index.

(b) *Strategies Employed for Achieving Objectives*

The Center relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends) to achieve its long-term rate of return objectives. The Center utilizes an efficient frontier approach to establish the appropriate asset allocation balancing long-term return objectives within prudent risk constraints. The Investment Committee of the Center's board of trustees reviews the Center's asset allocation at least once a year.

(c) *Spending Policies and How the Investment Objectives Relate to Spending Policies*

The Center's spending policy for endowment funds is to appropriate for distribution each year 5% of the endowment fund's average fair value over the prior three years, provided that the fair value of the endowment fund exceeds the corpus. For a portion of the Center's board-designated investments, the Center does not appropriate for distribution any amount of investment return as all of the return earned is held to grow the fund for future repayment of long-term debt. For the remaining board-designated investments, the Center makes all investment return available for expenditure to support research. In establishing these policies, the Center considered the long-term expected returns on its endowment and board-designated investments.

(d) *Funds with Deficiencies*

Unless otherwise agreed with the donor, the Center's policy has been to maintain the value of the original corpus of each individual donor-restricted endowment fund. From time to time, the fair value of assets in such endowment funds may fall below this level or such other level as may have been agreed to by the donor or required by law. Losses on the investments of a donor-restricted endowment fund reduce temporarily restricted net assets to the extent that donor-imposed restrictions on net appreciation of the fund have not been met before a loss occurs and any remaining loss reduces unrestricted net assets. As of June 30, 2015 and 2014, the aggregate reduction from unrestricted net assets totaled \$3 and \$0, respectively.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

The following tables show the net asset composition of the Center's endowment funds by type of fund as of June 30, 2015 and 2014:

		2015			
		Unrestricted	Temporarily restricted	Permanently restricted	Total
Donor-restricted endowment funds	\$	(3)	13,253	31,549	44,799
Board-designated endowment funds		97,275	—	—	97,275
Total	\$	<u>97,272</u>	<u>13,253</u>	<u>31,549</u>	<u>142,074</u>

		2014			
		Unrestricted	Temporarily restricted	Permanently restricted	Total
Donor-restricted endowment funds	\$	—	16,053	28,607	44,660
Board-designated endowment funds		99,553	—	—	99,553
Total	\$	<u>99,553</u>	<u>16,053</u>	<u>28,607</u>	<u>144,213</u>

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

The following tables show the activity that has occurred within the endowment net asset accounts for the years ended June 30, 2015 and 2014:

	2015			Total
	Unrestricted	Temporarily restricted	Permanently restricted	
Endowment net assets, beginning of year	\$ 99,553	16,053	28,607	144,213
Investment return:				
Investment income	603	269	—	872
Net realized gain	769	784	—	1,553
Net unrealized loss	(2,246)	(1,418)	—	(3,664)
Total investment return	(874)	(365)	—	(1,239)
Contributions	—	20	2,942	2,962
Distributions	—	—	—	—
Board transfers in	—	—	—	—
Board transfers out	(1,407)	—	—	(1,407)
Appropriation of endowment assets for expenditure	—	(2,455)	—	(2,455)
Endowment net assets, end of year	\$ <u>97,272</u>	<u>13,253</u>	<u>31,549</u>	<u>142,074</u>

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

	2014			Total
	Unrestricted	Temporarily restricted	Permanently restricted	
Endowment net assets, beginning of year	\$ 85,626	11,305	27,286	124,217
Investment return:				
Investment income	541	193	—	734
Net realized gain	6,462	1,781	—	8,243
Net unrealized gain	7,757	2,863	—	10,620
Total investment return	14,760	4,837	—	19,597
Contributions	—	1,062	1,321	2,383
Distributions	(1,018)	—	—	(1,018)
Board transfers in	1,934	—	—	1,934
Board transfers out	(1,749)	—	—	(1,749)
Appropriation of endowment assets for expenditure	—	(1,151)	—	(1,151)
Endowment net assets, end of year	\$ 99,553	16,053	28,607	144,213

Contributions to the endowment are only recognized when cash is received; pledges are recorded outside of the endowment until collected.

(6) Land, Buildings, and Equipment

Summaries of land, buildings and equipment at cost as of June 30 are as follows:

	2015	2014
Land	\$ 52,389	52,389
Buildings and improvements	488,121	471,831
Equipment	146,021	132,558
Construction in progress	5,879	19,188
	692,410	675,966
Less accumulated depreciation	(326,983)	(309,062)
	\$ 365,427	366,904

Buildings are depreciated on a straight-line basis over 45 years, while improvements and equipment are depreciated over 3 to 30 years, depending on the nature of the asset. Interest expense on borrowed funds

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

during construction is a component of the cost of assets. The amount capitalized represents interest on funds expended for construction. Capitalization of interest ceases when the asset is placed in service. The Center had no capitalized interest in 2015 and 2014.

(7) Notes and Pledges Receivable

Components of notes and pledges receivable as of June 30 are as follows:

	<u>2015</u>	<u>2014</u>
Amounts due in:		
Less than one year	\$ 2,137	4,543
One to five years	4,575	2,588
Less:		
Unamortized discount	(13)	(31)
Allowance for uncollectible pledges	<u>(2,306)</u>	<u>(2,306)</u>
Notes and pledges receivable, net	<u>\$ 4,393</u>	<u>4,794</u>

As of June 30, 2015 and 2014, the gross notes and pledges receivable balances include pledges with a donor-restricted purpose of \$3,806 and \$4,009, respectively. The discounts on pledges are computed at the rate commensurate with the risks applicable to the year in which the promise is received. Notes and pledges have been discounted using a rate ranging from 2.5% to 5.0%.

(8) Long-Term Debt

Summaries of long-term debt as of June 30 are as follows:

	<u>2015</u>	<u>2014</u>
Series 2007 Revenue Bonds at a fixed interest rate of 4.72% secured by a deed of trust due in amount of \$4,359 in 2015	\$ —	4,359
Series 2009A Revenue Bonds at fixed interest rates ranging from 3.50% to 6.00% secured by a deed of trust due in amounts ranging from \$3,220 in 2015 to \$4,930 in 2033	100,785	103,975
Series 2010 Revenue Bonds at a variable interest rate averaging 1.45% and 1.48% for the years ended June 30, 2015 and 2014 secured by a deed of trust due in amounts ranging from \$1,021 in 2015 to \$2,228 in 2032	26,380	27,352
Series 2011A Revenue Bonds at fixed interest rates ranging from 0.50% to 6.00% secured by a deed of trust due in amounts ranging from \$1,125 in 2015 to \$4,795 in 2035	80,990	81,930

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

	<u>2015</u>	<u>2014</u>
Series 2012A Revenue Bonds at a variable interest rate averaging 1.27% and 1.23% for the years ended June 30, 2015 and 2014 secured by a deed of trust due in amounts ranging from \$6,110 in 2035 to \$9,165 in 2041	\$ 57,685	57,685
Series 2012B Revenue Bonds at a variable interest rate averaging 1.35% and 1.25% for the years ended June 30, 2015 and 2014 secured by a deed of trust due in amounts ranging from \$8,355 in 2035 to \$13,578 in 2041	84,800	84,800
Series 2014 Revenue Bonds at a variable interest rate averaging 0.82% for the year ended June 30, 2015 secured by a deed of trust due in amounts ranging from \$177 in 2015 to \$231 in 2039	4,288	—
	<u>354,928</u>	<u>360,101</u>
Unamortized (discount)	<u>(1,557)</u>	<u>(1,559)</u>
	<u>\$ 353,371</u>	<u>358,542</u>
Fair value disclosure (note 4)	\$ 380,289	383,498

On July 24, 2014, the Center issued through the Washington Health Care Facilities Authority (the Authority) \$4,435 of tax-exempt revenue bonds Series 2014 (2014 Bond). The 2014 Bond is a variable rate bond used to refund the 2007 Bond, which was used to reimburse the Center for the purchase of property on the Center's campus. The 2014 Bonds were issued under a private placement with JP Morgan Chase Bank, N.A. and all interest and principal payments are made directly to the bank. The deed of trust only secures the specific property on the Center's campus.

On August 30, 2012, the Center issued through the Authority (the Authority) \$57,685 of tax-exempt revenue bonds Series 2012A (2012A Bonds) and an \$84,800 tax-exempt revenue bond Series 2012B (2012B Bond). The 2012A Bonds are variable rate bonds used to refund the 2011B bonds. The 2012A Bonds were issued under a private placement with JP Morgan Chase Bank, N.A. The 2012B Bond is a variable rate bond used to refund the 2011C Bonds. The 2012B Bond was issued under a private placement with Bank of America, N.A. and all interest and principal payments are made directly to the bank.

On June 30, 2011, the Center issued through the Authority \$84,150 of tax-exempt revenue bonds Series 2011A (2011A Bonds), \$57,525 of tax-exempt revenue bonds Series 2011B (2011B Bonds) and \$84,500,000 of tax-exempt revenue bonds Series 2011C (2011C Bonds). The 2011A Bonds are fixed rate bonds issued under the Center's credit rating with interest rates ranging from 0.50% to 6.00% used to refund a portion of the 2001A Bonds and the 2009B Bonds. The 2011B Bonds are variable rate bonds used to refund a portion of the 2001A Bonds and the 2009B Bonds, and fund most of the repayment of a bridge loan used to acquire the 1100 Eastlake Building. The 2011C Bonds are variable rate bonds used to refund a portion of the 2001A Bonds and the 2009B Bonds, fund the remainder of the bridge loan repayment and fund the alterations to be made to the 1100 Eastlake Building.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

On November 4, 2010, the Center issued through the Authority a \$30,000 tax-exempt revenue bond Series 2010 (2010 Bond). The 2010 Bond is a variable rate bond used to purchase the Yale Building from National Healthcare Research and Education Finance Corporation (NHREFCO) (note 11). The 2010 Bond was issued under a private placement with JP Morgan Chase Bank, N.A. and all interest and principal payments are made directly to the bank.

On November 24, 2009, the Center issued through the Authority \$114,920 of tax-exempt revenue bonds Series 2009A (2009A Bonds). The 2009A Bonds are fixed rate bonds issued under the Center's credit rating with interest rates ranging from 3.50% to 6.00% and were used to refund the 2001B Bonds and 2002 Bonds.

On November 15, 2007, the Center issued through the Authority \$5,200 of tax-exempt revenue bonds Series 2007 (2007 Bonds). The 2007 Bonds are fixed rate bonds used to reimburse the Center for the purchase of property on the Center's campus. The deed of trust only secures the specific property on the Center's campus.

The bond documents for the 2009A Bonds, 2010 Bonds, 2011A Bonds, 2012A Bonds and 2012B Bonds have covenants that require the Center to provide to the Authority, pursuant to a deed of trust, a mortgage and security interest in substantially all of the real estate and improvements owned by the Center, a security interest in the funds held by the trustees, and in the gross receivables and equipment owned by the Center. The bond documents for the 2012A Bonds and 2012B Bond require the Center to maintain unrestricted and unencumbered cash, cash equivalents, and marketable debt and equity securities of at least 80 days of cash operating expenses less subaward expenses and net income available for debt service must exceed 150% of the debt service in the same year. The bond documents for the 2009A Bonds require the establishment and maintenance of a debt service reserve fund. Additional covenants include a restriction on the creation of additional liens on the Center's property, a restriction on the issuance of additional debt, and a requirement that net income available for debt service must exceed 125% of the debt service in the same year.

The following schedule shows future long-term maturities by year:

2016	\$	5,543
2017		5,954
2018		6,332
2019		6,764
2020		7,188
Thereafter		<u>323,147</u>
	\$	<u><u>354,928</u></u>

(9) Retirement Plan

The Center has a defined-contribution plan for its salaried employees. Employees are generally eligible after one year of service. The Center contributes 7% of each employee's compensation up to the Social Security wage base limit and 12% on compensation above that limit. For certain management employees, the Center contributes 10% of compensation up to the Social Security wage base limit and 15% above the limit.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

Retirement plan contributions for the years ended June 30, 2015 and 2014 was \$13,677 and \$13,473, respectively.

(10) Annuities

The Center administers, through a third party, gift annuities for which it is obligated to make periodic distributions to designated beneficiaries. When contributed assets are initially received, the assets are recorded at fair value within the investments balance, and contribution revenue is recorded equal to the value of the contributed assets received less the annuity liability. The present value of the payments due to the beneficiaries totaled \$3,500 and \$3,914 at June 30, 2015 and 2014, respectively. The annuity liability is revalued annually based upon actuarially computed present values. Present values are based on life expectancy and discount rates range between 4% and 10%. The Center maintains segregated funds that exceed the actuarial value of the annuity liability as required by state law. The gift annuity payable is recorded in accrued liabilities.

(11) Commitments and Contingencies

(a) Operating Leases

Certain equipment and facilities utilized by the Center in its operations are leased. The related future minimum rental payments for these operating leases with noncancelable terms in excess of one year as of June 30, 2015 are as follows:

2016	\$	2,550
2017		2,556
2018		1,632
2019		1,353
2020		1,389
Thereafter		5,013
	\$	<u>14,493</u>

Rental expense for all operating leases for the years ended June 30, 2015 and 2014 was \$4,138 and \$4,478, respectively.

In conjunction with purchase and renovation of office and lab space in the 1100 Eastlake Building, the Center gave notice on March 31, 2011 of its intent to terminate its lease obligation for the 1616 Eastlake Building. Under the terms of the operating lease, beginning on October 1, 2012, the Center reduced the amount of space leased from approximately 106,000 net rentable square feet to approximately 40,000 net rentable square feet. The lease term for most of the 40,000 net rentable square feet extends through September 30, 2017. On May 11, 2012, the Center entered into a lease amendment to reduce the amount of space leased by approximately 13,000 net rentable square feet to approximately 27,000 net rentable square feet. The Center expects to continue to utilize the office portion of this space and has subleased the lab portion of this space as of June 30, 2015.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

(b) *Litigation and Compliance with Laws and Regulations*

The Center is involved in litigation and regulatory investigations arising in the normal course of its business. After consultation with legal counsel, management estimates that these matters will be resolved without material adverse effect on the Center's future financial position or results from operations.

The research industry is subject to numerous federal, state, and local laws and regulations. Some of these laws govern licensure, accreditation, and government program participation requirements. Government agencies are actively conducting investigations concerning possible violations of these statutes and regulations by research facilities. Violations of these laws and regulations could result in expulsion from government programs, together with the imposition of significant fines and penalties. Management believes that the Center is in material compliance with all applicable laws and regulations. Compliance with laws and regulations is subject to future government review and interpretation of such laws and regulations as well as regulatory actions unknown or unasserted at this time.

(c) *Contingent Liability*

The Center received federal grant funding for a portion of the construction of its South Lake Union Campus. Because the Center received federal grant funding for a portion of this facility, the government retains an interest in the net proceeds received if the facility is sold. The Center has not recorded any liability related to this interest as it is contingent upon the sale of the facility, and management has determined the probability of this transaction occurring to be remote.

(12) Professional Liability Insurance

The Center has claims-made professional and general liability insurance for 2015 and 2014. The Center has accrued an actuarial estimate of unreported instances and claims as of June 30, 2015, which is included in accounts payable.

(13) Related-Party Transactions

In June 1998, the SCCA was formed. The SCCA is a joint venture between the University of Washington Academic Medical Center (UWMC), Children's Hospital and Regional Medical Center (now Seattle Children's Hospital (Seattle Children's)), and the Center. As a separately incorporated nonprofit corporation, the SCCA is organized for the purpose of developing and offering a comprehensive program of integrated cancer care services in the Northwest that will enhance the cancer research, teaching, and clinical programs of the Center, UWMC, and Seattle Children's. The SCCA is one of several Medicare-designated cancer hospitals in the United States. Members of the SCCA share equally in capital contributions and in the results of operations. The SCCA began operations in January 2001. The SCCA coordinates adult inpatient services with the UWMC and pediatric inpatient services with Seattle Children's, while operating its own ambulatory cancer care service facility. The Center is accounting for its interest in the SCCA under the equity method.

Under the terms of the Members' Agreement, the Center has certain financial obligations to the SCCA, including funding its share of capital contributions. From 1998 through 2001, the Center contributed a total

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

of \$13,562 in cash capital contributions, which have been recorded as beneficial interest in assets of SCCA on the consolidated statements of financial position. The Center's obligations to the SCCA were fully paid as of June 30, 2001. In addition, in 2001 the Center contributed its existing outpatient cancer care program valued at \$12,124, equipment, supplies, and other assets valued at \$1,800, and a ground lease valued at \$3,600 to the SCCA. The Center records the amortization of these contributed assets in investment income.

The following is a summary of the SCCA's financial position and results as of and for the years ended June 30, 2015 and 2014:

	<u>2015</u>	<u>2014</u>
Assets	\$ 523,791	488,899
Liabilities	\$ 187,969	170,708
Net assets	<u>335,822</u>	<u>318,191</u>
Total liabilities and net assets	<u>\$ 523,791</u>	<u>488,899</u>
	<u>2015</u>	<u>2014</u>
Revenues	\$ 475,921	435,228
Less expenses	(441,517)	(408,155)
Plus nonoperating (loss) income	<u>(17,185)</u>	<u>7,689</u>
Excess of revenues over expenses	17,219	34,762
Net assets released from restriction for capital	—	270
Grant contributions restricted for capital acquisition	21	—
Net change in unrealized (losses) gains on investments	<u>(32)</u>	<u>(26)</u>
Increase in unrestricted net assets	<u>\$ 17,208</u>	<u>35,006</u>

The Center has entered into service agreements to provide support services to the SCCA. The service agreements are for administrative services, facilities usage, and patient care housing. The Center recognized \$16,956 and \$15,771 of other income for the years ended June 30, 2015 and 2014, respectively, as a result of these agreements.

The Center recognized other income (see below) for the years ended June 30, 2015 and 2014, respectively, for fees associated with licenses, data collection, and research and development services provided by the Center to the SCCA.

(14) Other Income

Other income includes income from noncore sources including service agreements, related party transactions (see Note 13), professional services, core resources, rent, parking and similar activities. The Center had \$38,150 and \$30,584 of Other Income for the years ended June 30, 2015 and 2014, respectively.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

(15) Clinical Service Fee Revenue

The Center has entered into inpatient service agreements with UWMC, Seattle Children's, and the SCCA for which the Center receives various payments related to research and development support, data collection and analysis, physician assistant services, consulting services, and license rights to use the Center's name in connection with the inpatient cancer services program. Fees for services during the years ended June 30, 2015 and 2014 from UWMC total \$10,414 and \$8,209, respectively, from Seattle Children's total \$642 and \$625 respectively, and from the SCCA total \$5,208 and \$6,346, respectively. Of these amounts, \$5,713 and \$5,711 are included in other receivables as of June 30, 2015 and 2014, respectively.

(16) Accounting for Derivative Instruments and Hedging Activities

Accounting principles require that every derivative instrument (including certain derivative instruments embedded in other contracts) be recorded on the statement of financial position as either an asset or liability measured at its fair value. These principles require that changes in the derivative instrument's fair value be recognized currently.

(a) *Interest Rate Swaps*

In October 2008, the Center entered into two interest rate swaps to replace the swaps that were terminated. One of the swaps was associated with the Series 2000 Bonds (Series 2000 Replacement Swap) and one is associated with the Series 2001A Bonds (Series 2001A Replacement Swap). The notional amount, timing of principal payments, and timing of interest payments for each of the Replacement Swaps are similar to the terms of the bonds with which they are associated. In the case of the Series 2000 Replacement Swap, the interest rate paid by the Center was fixed at 5.19% while the counterparty pays the Center an indexed rate plus 0.20%. In the case of the Series 2001A Replacement Swap, the interest rate paid by the Center was fixed at 4.97% while the counterparty pays the Center an indexed rate plus 0.20%. Upon entering into the Replacement Swaps, the Center received a payment of \$7,150 for the Series 2000 Replacement Swap and \$7,690 for the Series 2001A Replacement Swap from the counterparty. These payments were recorded as deferred credits on cash flow hedges on the statement of financial position. The fair value is the estimated amount the bank would receive or pay to terminate the swap agreement at the reporting date, taking into account current interest rates and the current creditworthiness of the swap counterparties. The fair value of the Series 2000 Replacement Swap included in liabilities was \$11,756 at June 30, 2015 and \$11,961 at June 30, 2014. The fair value of the Series 2001A Replacement Swap included in liabilities was \$16,928 at June 30, 2015 and \$16,825 at June 30, 2014. The fair value of the swap instruments will change in future time periods as interest rates change and as the time period remaining for the hedged transaction shortens. Provided that the Center holds the swaps to maturity, the value of the derivative will be zero.

(b) *Amendment to Series 2001A Replacement Swap*

In May 2011, the Center amended the Series 2001A Replacement Swap to change the rate paid by the counterparty from a tax-exempt indexed rate plus 0.20% to 67% of three month LIBOR plus 0.64%. All other terms of the Series 2001A Replacement Swap, including notional amount, timing, and amount of principal payments remain unchanged.

FRED HUTCHINSON CANCER RESEARCH CENTER

Notes to Consolidated Financial Statements

June 30, 2015 and 2014

(In thousands)

(c) Collateral Posted with Swap Counterparty

The replacement swap agreements contain terms that require the Center to post collateral with the counterparty if certain conditions are met, including the mark-to-market amount to terminate the Series 2000 Replacement Swap and the Series 2001A Replacement swap exceeds \$20,000. Collateral of \$8,400 and \$0 was posted as of June 30, 2015 and 2014, respectively.

(17) Subsequent Events

The Center evaluated subsequent events from June 30, 2014 to October 22, 2015 the date on which these financial statements were issued.

On July 8, 2015, the Center issued through the Authority \$78,510 of tax-exempt revenue bonds Series 2015 (2015 Bonds). The 2015 Bonds are fixed rate bonds used to advance refund and defease a portion of the 2009A Bonds. The portion of the 2009A bonds that were defeased by the 2015 Bonds totaled \$80,865 and represented the term bonds maturing on January 1, 2024 and January 1, 2033. These bonds were placed into escrow along with the proceeds of the 2015 bonds and principal and interest payments will be made to bondholders through the call date, July 1, 2019. The remaining 2009A serial bonds maturing through January 1, 2020, totaling \$19,920, are still outstanding as a liability for the Center.



KPMG LLP
Suite 2900
1918 Eighth Avenue
Seattle, WA 98101

Independent Auditors' Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

The Board of Trustees
Fred Hutchinson Cancer Research Center:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Fred Hutchinson Cancer Research Center (the Center), which comprise the consolidated balance sheets as of June 30, 2015 and 2014, and the related consolidated statements of activities statement of functional expenses, and cash flows for the years then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated October 22, 2015.

Internal Control over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the Center's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Center's internal control. Accordingly, we do not express an opinion on the effectiveness of the Center's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Center's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an



opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Center's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Center's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

October 22, 2015



KPMG LLP
Suite 2900
1918 Eighth Avenue
Seattle, WA 98101

**Independent Auditors' Report on Compliance for Each Major Program;
Report on Internal Control Over Compliance; and Report on Schedule of
Expenditures of Federal Awards Required by OMB Circular A-133,
*Audits of States, Local Governments, and Non-Profit Organizations***

The Board of Trustees
Fred Hutchinson Cancer Research Center:

Report on Compliance for Each Major Federal Program

We have audited Fred Hutchinson Cancer Research Center's (the Center) compliance with the types of compliance requirements described in the OMB Circular A-133 Compliance Supplement that could have a direct and material effect on each of the Center's major federal programs for the year ended June 30, 2015. The Center's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with the requirements of laws, regulations, contracts, and grants applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of the Center's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and OMB Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Those standards and OMB Circular A-133 require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the Center's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of the Center's compliance.

Opinion on Each Major Federal Program

In our opinion, the Center complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2015.



Report on Internal Control Over Compliance

Management of the Center is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the Center's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with OMB Circular A-133, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the Center's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of OMB Circular A-133. Accordingly, this report is not suitable for any other purpose.



Report on Schedule of Expenditures of Federal Awards Required by OMB Circular A-133

We have audited the consolidated financial statements of the Center as of and for the year ended June 30, 2015, and have issued our report thereon dated October 22, 2015, which contained an unmodified opinion on those financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by OMB Circular A-133 and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

KPMG LLP

October 22, 2015

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards

Year ended June 30, 2015

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Expenditures
	DIRECT RESEARCH AND DEVELOPMENT AWARDS	
	DEPARTMENT OF HEALTH AND HUMAN SERVICES / NATIONAL INSTITUTES OF HEALTH	
Unknown	NATIONAL CANCER INSTITUTE	\$ 11,002,739
93.393	NATIONAL CANCER INSTITUTE	25,387,368
93.394	NATIONAL CANCER INSTITUTE	13,983,508
93.395	NATIONAL CANCER INSTITUTE	24,107,979
93.396	NATIONAL CANCER INSTITUTE	4,524,848
93.397	NATIONAL CANCER INSTITUTE	17,288,933
93.398	NATIONAL CANCER INSTITUTE	2,946,203
93.399	NATIONAL CANCER INSTITUTE	1,695,639
93.855	NATIONAL CANCER INSTITUTE	977,012
93.307	NATIONAL CENTER ON MINORITY HEALTH & DIS	450,720
93.279	NATIONAL INSTITUTE ON DRUG ABUSE	2,033,419
Unknown	NATIONAL MARROW DONOR PROGRAM	52,690
93.839	NATIONAL MARROW DONOR PROGRAM	205,656
Unknown	NATL HEART, LUNG AND BLOOD INSTITUTE	11,494,106
93.837	NATL HEART, LUNG AND BLOOD INSTITUTE	7,869,239
93.838	NATL HEART, LUNG AND BLOOD INSTITUTE	1,306,400
93.839	NATL HEART, LUNG AND BLOOD INSTITUTE	4,204,308
93.172	NATL HUMAN GENOME RESEARCH INSTITUTE	2,185,647
93.301	NATL HUMAN GENOME RESEARCH INSTITUTE	1,499
93.310	NATL HUMAN GENOME RESEARCH INSTITUTE	6,472
Unknown	NATL INST OF ALLERGY AND INFECTIOUS DSE	362,252
93.855	NATL INST OF ALLERGY AND INFECTIOUS DSE	82,705,525
93.856	NATL INST OF ALLERGY AND INFECTIOUS DSE	(845)
93.846	NATL INST OF ARTH AND MUSC SKIN AND DSE	1,394,658
93.172	NATL INST OF CHILD HEALTH & HUMAN DEV	466,317
93.865	NATL INST OF CHILD HEALTH & HUMAN DEV	1,161,880
93.121	NATL INST OF DENTAL CRANIO RESEARCH	617,383
93.847	NATL INST OF DIAB AND DIGST AND KDNV DSE	5,906,350
93.113	NATL INST OF ENVIRONMENTAL HEALTH SCI	1,808,098
93.839	NATL INST OF GENERAL MEDICAL SCIENCES	31,763
93.859	NATL INST OF GENERAL MEDICAL SCIENCES	9,423,908
93.242	NATL INST OF MENTAL HEALTH	328,157
93.853	NATL INST OF NEURO DISORDERS AND STROKE	2,473,257
93.173	NATL INST ON DEAFNESS AND COMM DISORDER	86,531
93.286	NATL INSTITUTE OF BIOMED IMAGING & BIOE	277,283
93.866	NATL INSTITUTE ON AGING	2,277,559
93.310	OFFICE OF THE DIRECTOR, NIH	469,909
93.351	OFFICE OF THE DIRECTOR, NIH	423,135
	DIRECT FUNDING / OTHER FEDERAL AGENCIES	
12.420	DEPARTMENT OF DEFENSE	2,225,105
12.910	DEPARTMENT OF THE INTERIOR (DARPA)	(231)
Unknown	DEPARTMENT OF VETERANS AFFAIRS	20,712
Unknown	CENTERS FOR DISEASE CONTROL AND PRV	124,357
47.049	NATIONAL SCIENCE FOUNDATION	120,139
47.070	NATIONAL SCIENCE FOUNDATION	762,777
47.074	NATIONAL SCIENCE FOUNDATION	345,842
12.431	US ARMY	806,482
	GRANT TOTAL -DIRECT RESEARCH AND DEVELOPMENT	\$ <u>246,342,688</u>

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards
Year ended June 30, 2015

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period-end	Expenditures
	PASS-THROUGH FUNDS – DEPARTMENT OF HEALTH AND HUMAN SERVICES AND OTHER FEDERAL AGENCIES:				
93.839	ADAPTIVE BIOTECHNOLOGIES CORPORATION CORRELATING TCR DIVERSITY TO IMMUNE RECONSTITUTION AFTER CORD BLOOD TRANSPLANT	FHCRC106969-02	2013-09-10	2015-02-28	\$ 118,797
10.421	ALBERT EINSTEIN COLLEGE OF MEDICINE MOLECULAR METHODS TO IMPROVE CERVICAL CANCER SCREENING IN HIV+ WOMEN	31528A	2013-09-01	2015-08-31	79,724
93.393	PROTEIN-SPECIFIC ANTIBODIES TO HELICOBACTER PYLORI AND COLORECTAL CANCER RISK	AWOA	2015-05-01	2016-04-30	650
93.855	DRUG AT THE RIGHT PLACE AND CONCENTRATION: OPTIMIZING COMBINATION VAGINAL RING PREP	PO177919-31084M	2015-01-01	2015-12-31	11,049
93.393	ARIZONA STATE UNIVERSITY A CENTER FOR THE CONVERGENCE OF PHYSICAL SCIENCE AND CANCER BIOLOGY	14-346	2013-09-01	2014-08-31	3,385
93.393	A CENTER FOR THE CONVERGENCE OF PHYSICAL SCIENCE AND CANCER BIOLOGY/CORE 2: MATERIALS CORE	14-345	2013-09-01	2014-08-31	23,858
93.213	BASTYR UNIVERSITY BASTRY/UW ONCOMYOLOGY TRANSLATIONAL RESEARCH CENTER	H34B11-03 (4)	2013-09-01	2014-08-31	1,878
93.213	BREAST CANCER INTEGRATIVE ONCOLOGY: PROSPECTIVE MATCHED CONTROLLED OUTCOMES STUDY	H33B11-01 (5)	2014-05-01	2015-04-30	215,056
93.393	BAYLOR COLLEGE OF MEDICINE ADVANCED GLYCATION END PRODUCTS AND RISK OF PANCREATIC CANCER	5600955946	2013-09-20	2016-07-31	28,203
93.393	BECKMAN RESEARCH INSTITUTE -CITY OF HOPE ROLE OF GENETIC SUSCEPTIBILITY IN THERAPY-RELATED SUBSEQUENT MALIGNANCIES	22175.915021.6693	2013-12-01	2014-11-30	8,286
93.397	CITY OF HOPE LYMPHOMA SPORE	22679.916790.6693	2013-09-06	2014-08-31	53,896
93.397	CITY OF HOPE LYMPHOMA SPORE	22679.916790.669399	2014-09-01	2015-08-31	126,414
93.846	BENAROYA RESEARCH INSTITUTE EVOLVING ADAPTIVE AND EFFECTOR MECHANISMS FROM PRE-RA THROUGH ESTABLISHED DISEASE	FY15301401	2014-09-24	2015-05-31	4,092
93.855	IMMUNE TOLERANCE NETWORK	FY15ITN025	2014-05-01	2015-11-30	96,998
93.396	BETH ISRAEL DEACONESS MEDICAL CENTER PROJECT 1: STEROID METABOLISM IN CASTRATION-RESISTANT PROSTATE CANCER	01027365	2014-05-01	2015-04-30	297,921
93.396	ANDROGEN RECEPTOR ACTION IN CASTRATION RESISTANT PROSTATE CANCER (PROJECT 3)	01027368	2014-05-01	2015-04-30	117,060
93.396	CORE A: ADMINISTRATIVE/CLINICAL/BIOSTATISTICS	01027362	2014-05-01	2015-04-30	17,505
93.396	PROJECT 1: STEROID METABOLISM IN CASTRATION-RESISTANT PROSTATE CANCER	01028034	2015-05-01	2016-04-30	72,815
93.396	CORE A: ADMINISTRATIVE/CLINICAL/BIOSTATISTICS	01028031	2015-05-01	2016-04-30	3,726
93.396	ANDROGEN RECEPTOR ACTION IN CASTRATION RESISTANT PROSTATE CANCER (PROJECT 3)	01028037	2015-05-01	2016-04-30	14,971
93.867	BOARD OF REGENTS OF UNIV OF WISCONSIN SY MACULAR PIGMENT IN AGING AND DISEASE	610K330	2015-06-01	2016-05-31	1,787
93.172	BOSTON UNIVERSITY METHODS FOR THE ANALYSIS AND INTEGRATIONS OF NEXT-GENERATION SEQUENCING	4500000944	2012-03-01	2015-02-28	83,030
0.000	BRIGHAM & WOMEN'S HOSPITAL METABOLOMICS OF CHD IN THE WHI	109102	2014-03-29	2015-03-28	17,463
0.000	METABOLOMICS OF CHD IN THE WHI	109102	2015-03-29	2016-03-28	3,818
93.394	BROAD INSTITUTE PROTEO-GENOMIC DISCOVERY, PRIORITIZATION AND VERIFICATION OF CANCER BIOMARKERS	6610200-5500000391	2011-08-26	2012-07-31	19
93.394	PROTEO-GENOMIC DISCOVERY, PRIORITIZATION AND VERIFICATION OF CANCER BIOMARKERS	6610203-5500000391	2013-08-01	2014-07-31	158,268
93.394	PROTEO-GENOMIC DISCOVERY, PRIORITIZATION AND VERIFICATION OF CANCER BIOMARKERS	6610203-5500000391	2013-08-01	2014-07-31	15,237
93.394	PROTEO-GENOMIC DISCOVERY, PRIORITIZATION AND VERIFICATION OF CANCER BIOMARKERS	6610204-5500000391	2014-08-01	2015-07-31	1,150,098
93.113	BROWN UNIVERSITY AMBIENT AIR POLLUTION AND INCIDENT STROKE	00000541	2012-07-01	2013-03-31	5,025
93.399	CASE WESTERN RESERVE UNIVERSITY GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA	RES508419	2013-09-01	2014-08-31	30,691
93.399	GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA	RES509322	2014-09-01	2015-08-31	103,119
93.399	GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA - SUPPLEMENT 1	RES509330	2014-09-01	2015-08-31	6,639
93.399	GENETIC DETERMINANTS OF BARRETT'S ESOPHAGUS - SUPPLEMENT 2	RES509332	2014-09-01	2015-08-31	33,515
93.396	CEDARS-SINAI MEDICAL CENTER PROSTATE CANCER BONE METASTASIS: BIOLOGY AND TARGETING/PATHOLOGY AND LABORATORY SUPPORT CORE	0000981041	2013-08-01	2014-07-31	603
93.396	CLEVELAND CLINIC LERNER COLLEGE OF MED NON-NEOPLASTIC CELL TYPES DICTATE GLIOMAGENESIS	409-SUB	2013-09-01	2014-08-31	67,716
93.396	NON-NEOPLASTIC CELL TYPES DICTATE GLIOMAGENESIS	528-SUB	2014-09-01	2015-06-30	95,891
93.395	COLUMBIA UNIVERSITY MEDICAL CENTER USING SWOG-MEDICARE DATABASE TO EVALUATE LONG-TERM TOXICITIES OF CANCER SURVIVORS	GG007556	2013-02-15	2016-01-31	13,216
93.067	RAPID SCALE-UP OF HIV/AIDS CARE AND TREATMENT SERVICES IN KINGDOM OF SWAZILAND	U2GPS002005-05	2013-09-30	2015-05-31	157,051
	ADVANCING CAPACITY FOR HIV IMPACT EVALUATIONS (ACHIEVE)	AWOA	2014-09-30	2015-09-29	37,437
93.394	CORNELL UNIVERSITY PRECISION MEDICINE APPROACH TO PROSTATE CANCER ACTIVE SURVEILLANCE	13121644-02	2014-08-01	2015-07-31	40,197
0.000	COURTESY ASSOCIATES BURKITT LYMPHOMA TRIAL NETWORK - OPERATING CENTER	GS-23F-0274M-59-2014	2014-09-19	2015-09-14	494,567
93.397	DANA-FARBER CANCER INSTITUTE EVOLUTIONARY DYNAMICS OF BRAIN, LUNG, AND HEMATOPOIETIC TUMORS: PROJECT #1	1197005	2013-09-01	2015-08-31	84,210
93.397	EVOLUTIONARY DYNAMICS OF BRAIN, LUNG, AND HEMATOPOIETIC TUMORS: PROJECT #4	1197405	2013-09-01	2015-08-31	36,626
93.397	EVOLUTIONARY DYNAMICS OF BRAIN, LUNG, AND HEMATOPOIETIC TUMORS: PROJECT #2	1197105	2013-09-01	2015-08-31	47,978
93.397	EVOLUTIONARY DYNAMICS OF BRAIN, LUNG, AND HEMATOPOIETIC TUMORS: PROJECT #3	1197205	2013-09-01	2015-08-31	47,550

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards
Year ended June 30, 2015

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period end	Expenditures
93.855	FUNCTIONAL GENOMIC ANALYSIS OF THE CD8 T CELL RESPONSE TO HIV VACCINES IN HUMANS	1194804	2013-09-01	2014-08-31	\$ 58,165
93.855	FUNCTIONAL GENOMIC ANALYSIS OF THE CD8 T CELL RESPONSE TO HIV VACCINES IN HUMANS	1194805	2014-09-01	2015-08-31	187,322
	DATA NUMERICA INSTITUTE, INC.				
93.859	STATISTICAL METHODS FOR INCOMPLETE DATA WITH MEASUREMENT ERRORS	AWOA	2015-05-01	2016-04-30	1,015
	DUKE UNIVERSITY				
0.000	SCOT: A RANDOMIZED, OPEN-LABEL, PHASE II/III MULTICENTER STUDY OF HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY	HHSN272201100025C-S2	2014-11-01	2015-10-31	8,809
	EAST CAROLINA UNIVERSITY				
93.859	THE GENETIC BASIS FOR REDUCED SEXUAL DIMORPHISM IN STICKLEBACK THROAT COLORATION	A14-0166-S001	2014-07-01	2016-06-30	23,425
	EMORY UNIVERSITY				
93.172	ENHANCED GENE IDENTIFICATION IN COMPLEX TRAITS USING KERNEL MACHINES	T088213	2013-09-04	2015-06-30	120,054
	FOGARTY INTERNATIONAL CENTER				
93.989	EXPANDING INDEPENDENT RESEARCH CAPACITY IN HIV-ASSOCIATED MALIGNANCIES IN UGANDA	D43 TW009759	2014-06-01	2015-03-31	72,524
93.989	EXPANDING INDEPENDENT RESEARCH CAPACITY IN HIV-ASSOCIATED MALIGNANCIES IN UGANDA	D43 TW009759	2015-04-01	2016-03-31	30,023
93.989	EXPANDING INDEPENDENT RESEARCH CAPACITY IN HIV-ASSOCIATED MALIGNANCIES IN UGANDA	D43 TW009759	2014-06-01	2015-03-31	46,496
93.989	EXPANDING INDEPENDENT RESEARCH CAPACITY IN HIV-ASSOCIATED MALIGNANCIES IN UGANDA	D43 TW009759	2015-04-01	2016-03-31	25,271
	GEORGETOWN UNIVERSITY				
93.846	VALIDATION OF PROMIS IN DIVERSE CANCER POPULATIONS	4442-007-FHCRC	2012-08-01	2014-07-31	14,467
93.393	OPTIMIZING PERSONALIZED CARE USING ECONOMIC STUDIES OF GENOMIC TESTING	RX 4442-041-FHCRC	2013-09-25	2014-08-31	18,140
93.393	OPTIMIZING PERSONALIZED CARE USING ECONOMIC STUDIES OF GENOMIC TESTING	410105_GR409753-FHCR	2014-09-01	2015-08-31	67,782
93.310	OPTIMIZING PERSONALIZED CARE USING ECONOMIC STUDIES OF GENOMIC TESTING - ADMIN SUPP	410856_GR410706-FHCR	2014-09-01	2015-08-31	60,888
	GEORGIA INSTITUTE OF TECHNOLOGY				
93.867	NANOMEDICINE CENTER FOR NUCLEOPROTEIN MACHINES	R7747-G17	2014-08-01	2015-02-28	61,669
	GROUP HEALTH COOPERATIVE				
93.172	GENETIC DISCOVERY AND APPLICATION IN A CLINICAL SETTING: CONTINUING A PARTNERSHIP	2013156521	2013-08-01	2014-07-31	2,382
93.172	GENETIC DISCOVERY AND APPLICATION IN A CLINICAL SETTING: CONTINUING A PARTNERSHIP	2014197254	2014-08-01	2015-07-31	28,267
	GYNECOLOGIC ONCOLOGY GROUP				
93.395	GYNECOLOGICAL ONCOLOGY GROUP	27469-23	2004-04-01	2016-03-31	46,067
	H. LEE MOFFITT CANCER CENTER & RES. INST				
93.393	FOLLOW-UP OF OVARIAN CANCER GENETIC ASSOCIATION AND INTERACTION STUDIES (FOCI)	10-15915-04-05-G2	2013-07-01	2014-06-30	1,236
	HARVARD UNIVERSITY				
93.393	TRANSDISCIPLINARY CANCER GENOMICS RESEARCH: POST-GWA INITIATIVE	114080.5029131	2013-07-01	2015-06-30	35,478
93.853	PROSPECTIVE STUDY OF BIOMARKERS AND RISK FACTORS FOR ALS INCIDENCE AND PROGRESSION	111131-5091009	2014-07-01	2016-06-30	16,860
	HEALTH RESEARCH INC				
93.393	FLAXSEED EFFECTS ON HORMONES AND LIGNANS: ROLE OF RACE, GENES, AND GUT MICROBIOME	83-01	2012-09-25	2014-08-31	82,174
93.393	FLAXSEED EFFECTS ON HORMONES AND LIGNANS: ROLE OF RACE, GENES, AND GUT MICROBIOME	83-02	2014-09-01	2015-08-31	186,594
	HENRY M. JACKSON FOUNDATION				
0.000	STATISTICAL AND DATA MANAGEMENT SUPPORT FOR ANALYSIS RELATED TO VACCINE TRIAL (RV144) AND ASSOCIATED TRIALS	10/792087	2013-10-01	2014-09-30	88,984
0.000	STATISTICAL AND DATA MANAGEMENT SUPPORT FOR ANALYSIS RELATED TO VACCINE TRIAL (RV144) AND ASSOCIATED TRIALS	10/792087	2014-10-01	2015-09-30	180,009
	ILLIONIX LLC				
0.000	DDMP: A SYSTEM FOR AUTOMATED COLLECTION, STORAGE, ANALYSIS AND REPORTING OF ANNOTATED DIETARY DATA	NA	2015-06-03	2015-09-15	5,581
	INDIANA UNIVERSITY-PURDUE UNIVERSITY IND				
93.865	BRIDGING PEDIATRIC AND ADULT BIOMARKERS OF GRAFT-VERSUS-HOST DISEASE	IN4689628FHCR	2013-08-01	2016-05-31	55,813
	INTERNATIONAL AGENCY FOR RESEARCH ON CAN				
93.393	ONE-CARBON METABOLISM BIOMARKERS AND LUNG CANCER RISK	GEP/12/02	2012-01-31	2016-06-30	27,924
	IOWA STATE UNIVERSITY				
93.862	DNA TARGETING BY TAL EFFECTORS	430-46-05A	2011-09-01	2016-04-30	100,420
	JOHNS HOPKINS UNIVERSITY				
93.855	EPIDEMIOLOGY AND ECOLOGY OF VIBRIO CHOLERAE IN BANGLADESH	2000990845	2010-06-15	2015-05-31	86,990
93.837	MECHANISMS OF GVHD PREVENTION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE	2001-414485	2011-12-15	2015-11-30	144,040
93.859	CENTER FOR SYSTEMS BIOLOGY OF RETROTRANSPOSITION	AWOA	2013-09-05	2013-09-06	(97,861)
12.420	PROSPECTIVE EVALUATION OF INTRAPROSTATIC INFLAMMATION AND FOCAL ATROPHY AS A PREDICTOR OF RISK OF HIGH-GRADE PROSTATE CANCER AND RECURRENCE AFTER PROSTATECTOMY	2002119729	2014-01-01	2014-12-31	13,461
	KAISER FOUNDATION RESEARCH INSTITUTE				
93.393	CRN4: CANCER RESEARCH RESOURCES AND COLLABORATION IN INTEGRATED HEALTH CARE SYSTEMS	115-9341-FHCRC-01	2013-09-01	2014-08-31	6,708
93.865	APPROPRIATE GESTATIONAL WEIGHT GAIN IN OVERWEIGHT/OBESE WOMEN	115-9446-1	2014-03-01	2016-02-29	75,803
93.393	CRN4: CANCER RESEARCH RESOURCES AND COLLABORATION IN INTEGRATED HEALTH CARE SYSTEMS	115-9341-FHCRC-01 AM	2014-09-01	2015-08-31	22,124
	LEIDOS BIOMEDICAL RESEARCH, INC				
0.000	FHCRC ORALCHIP STUDY	12XS531 - ST01	2012-11-07	2014-12-31	43,143
0.000	REPOSITORY OF MOUSE TISSUES AND PLASMA	12XS485	2012-07-01	2015-06-30	21,058
0.000	AMC HIV POSITIVE TUMOR MOLECULAR CHARACTERIZATION PROJECT	13ST4122	2013-07-02	2015-03-31	28,647
0.000	AMC HIV POSITIVE TUMOR MOLECULAR CHARACTERIZATION PROJECT	13ST4122	2013-07-02	2015-03-31	13,289
0.000	EXPANDING CAPACITY FOR INFECTION-RELATED CANCER RESEARCH BY EXAMINING THE CONTRIBUTION OF VIRAL GENOMIC DIVERSITY TO THE CLINICAL MANIFESTATIONS OF CANCER IN UGANDA	14X067	2014-03-07	2015-09-25	110,061
0.000	EXPANDING CAPACITY FOR INFECTION-RELATED CANCER RESEARCH BY EXAMINING THE CONTRIBUTION OF VIRAL GENOMIC DIVERSITY TO THE CLINICAL MANIFESTATIONS OF CANCER IN UGANDA	14X067	2014-03-07	2015-09-25	21,891
0.000	GENERATING EMPIRICALLY DETERMINED PROTEIN SIGNALING NETWORKS TO INTERPRET TCGA TUMOR PROFILES	14XS040	2014-04-04	2015-09-25	118,071

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards

Year ended June 30, 2015

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period end	Expenditures
0.000	MRM-BASED QUANTIFICATION OF PROTEINS AND PHOSPHOPEPTIDES IN THE RAS SIGNALING PATHWAY	14X092	2014-09-11	2016-09-10	\$ 192,109
0.000	HIV POSITIVE TUMOR GENOMICS PROJECT	15X083	2015-06-03	2016-12-02	14,447
0.000	HIV POSITIVE TUMOR GENOMICS PROJECT	15X083	2015-06-03	2016-12-02	10,834
	MAGEE-WOMEN'S RESEARCH INSTITUTE & FOUND				
93.855	MICROBICIDE TRIALS NETWORK: MTN - BEHAVIORAL ANALYSIS	9288	2014-01-01	2014-11-30	383,260
93.855	MICROBICIDE TRIALS NETWORK: MTN-003	9308	2014-01-01	2014-11-30	125,226
93.855	MICROBICIDE TRIALS NETWORK: MTN-024	9310	2014-01-01	2014-11-30	57,099
93.855	MICROBICIDE TRIALS NETWORK: MTN-023	9309	2014-01-01	2014-11-30	65,921
93.855	MTN-014: A PHASE 1 CROSSOVER TRIAL EVALUATING THE PHARMACOKINETICS OF TENOFOVIR REDUCED-GLYCERIN 1% GEL IN THE RECTAL AND VAGINAL COMPARTMENTS IN WOMEN	9311	2014-01-01	2014-11-30	55,709
93.855	MICROBICIDE TRIALS NETWORK: 015	9361	2014-12-01	2015-11-30	107,445
93.855	MICROBICIDE TRIALS NETWORK: MTN-003	9308	2014-01-01	2014-11-30	273,620
93.855	MICROBICIDE TRIALS NETWORK: 015	9361	2014-12-01	2015-11-30	64,984
93.855	MICROBICIDE TRIALS NETWORK: 015	9361	2014-12-01	2015-11-30	177,512
93.855	MICROBICIDE TRIALS NETWORK: 015	9361	2014-12-01	2015-11-30	1,066,691
93.855	MICROBICIDE TRIALS NETWORK: 015	9361	2014-12-01	2015-11-30	177,809
93.855	MICROBICIDE TRIALS NETWORK: 015	9361	2014-12-01	2015-11-30	86,447
93.855	MICROBICIDE TRIALS NETWORK: 015	9361	2014-12-01	2015-11-30	5,515
93.855	MICROBICIDE TRIALS NETWORK: 015	9361	2014-12-01	2015-11-30	149,890
93.855	MICROBICIDE TRIALS NETWORK: 015	9361	2014-12-01	2015-11-30	218,658
93.855	MICROBICIDE TRIALS NETWORK: 015	9361	2014-12-01	2015-11-30	73,029
93.855	MICROBICIDE TRIALS NETWORK: 015	9361	2014-12-01	2015-11-30	5,209
	MASSACHUSETTS GENERAL HOSPITAL				
93.393	CONTROLLING ESOPHAGEAL CANCER IN THE US: A COLLABORATIVE MODELING PROJECT	217155	2013-09-01	2014-08-31	19,284
93.393	COMPARATIVE MODELING OF LUNG CANCER CONTROL POLICIES	217238	2014-08-31	2014-08-31	73,808
93.393	COMPARATIVE MODELING OF LUNG CANCER CONTROL POLICIES	217238	2014-09-01	2015-08-31	150,806
93.393	CONTROLLING ESOPHAGEAL CANCER IN THE US: A COMPARATIVE MODELING PROJECT	217155	2014-09-01	2015-08-31	155,811
	MAYO CLINIC				
93.393	PROSTATE CANCER SUSCEPTIBILITY: THE ICPG STUDY	63289773	2013-09-01	2014-08-31	14,912
93.855	BENCHMARKING AND STANDARDIZING HIGH DIMENSIONAL SINGLE CELL DATA ANALYSIS METHODS	63484624	2012-07-01	2014-06-30	(563)
93.855	INNATE PREDICTORS OF ADAPTIVE BCG AND HBV VACCINE-INDUCE RESPONSES IN BANGALORE ADOLESCENTS	63410674	2013-07-01	2014-06-30	10,130
93.855	ENABLING ADVANCED HIGH AND LOW LEVEL ANALYTICS FOR LUMINEX TECHNOLOGY	64006111	2013-10-01	2015-06-30	71,431
93.855	INTEGRATION OF HIPC DATA TO IDENTIFY COMMON SIGNATURES OF INFLUENZA VACCINATION RESPONSES	64006713	2014-01-01	2015-04-30	63,108
93.855	UNBIASED FUNCTIONAL PROFILING OF THE MUCOSAL-ASSOCIATED INVARIANT T CELL RESPONSE FOLLOWING MALARIA INFECTION	64006718	2013-07-01	2015-03-31	147,428
93.855	INNATE PREDICTORS OF ADAPTIVE BCG AND HBV VACCINE-INDUCED RESPONSES IN BANGALORE ADOLESCENTS	64004559	2014-07-01	2016-06-30	73,838
93.393	PROSTATE CANCER SUSCEPTIBILITY: THE ICPG STUDY	63779243	2014-09-01	2015-08-31	51,002
93.855	BIOINFORMATICS APPROACH TO INFLUENZA A/H1N1 VACCINE IMMUNE PROFILING	63754927	2014-09-30	2015-06-30	537,599
	MEDICAL COLLEGE OF WISCONSIN				
93.395	STOPPING TYROSINE KINASE INHIBITORS IN CML PATIENTS (STOP-TKIS)	1531818	2014-09-19	2015-08-31	22,473
	NATL SURG ADJ BREAST & BOWEL PRJ FNDN				
93.399	NSABP TREATMENT PROTOCOLS FEDERAL MASTER PURCHASED SERVICES AGREEMENT	TFED-247	2006-02-01	2014-12-31	33,072
93.399	NSABP PREVENTION MAIN MEMBER	PUG-YR28	2013-06-01	2014-07-31	3,921
	NEW YORK UNIVERSITY				
93.859	CENTER FOR SYSTEMS BIOLOGY OF RETROTRANSPOSITION	14-A0-00-002587-01	2014-01-01	2014-05-31	91,457
93.859	CENTER FOR SYSTEMS BIOLOGY OF RETROTRANSPOSITION	14-A0-00-002587-01	2014-06-01	2015-05-31	74,907
93.394	SABOR: CHILEAN-AMERICAN MESOTHELIOMA BIOMARKER PROJECT	13-A0-00-002126-01	2014-07-01	2015-06-30	106,979
93.859	CENTER FOR SYSTEMS BIOLOGY OF RETROTRANSPOSITION	14-A0-00-002587-01	2015-06-01	2016-05-31	7,458
	NORTHROP GRUMMAN SYS CORP				
0.000	HUMAN IMMUNOLOGY PROJECT CONSORTIUM DATABASE HIPC-DB_RESEARCH PORTAL	7500117318	2013-09-30	2014-09-29	144,060
	NRG ONCOLOGY				
93.395	NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER	FHCRC - YR.1	2014-04-17	2015-02-28	7,000
93.395	RESEARCH SUBAWARD AGREEMENT AMENDMENT - PROTOCOL SUPPORT COMMITTEE CO-CHAIR	KNUDSEN-YR. 2	2015-03-01	2016-02-29	4,809
	OHIO STATE UNIVERSITY RESEARCH FOUNDATIO				
93.395	ITSC FOR LEUKEMIA: NOVEL MOLECULAR STRATEGIES FOR NCTN INDIVIDUALIZED THERAPIES - PROJECT 4	RF01377880-60045247	2014-05-02	2015-02-28	123,227
93.395	ITSC FOR LEUKEMIA: NOVEL MOLECULAR STRATEGIES FOR NCTN INDIVIDUALIZED THERAPIES: PROJECT 1	RF01377878-60040661	2014-05-02	2015-02-28	11,917
93.395	ITSC FOR LEUKEMIA: NOVEL MOLECULAR STRATEGIES FOR NCTN INDIVIDUALIZED THERAPIES: PROJECT 3	60048935 PO RF014005	2015-03-01	2016-02-29	58,266
93.395	LEADERSHIP - ITSC FOR LEUKEMIA: NOVEL MOLECULAR STRATEGIES FOR NCTN INDIVIDUALIZED THERAPIES	60048932 PO RF014005	2015-03-01	2016-02-29	8,130
	OREGON HEALTH & SCIENCE UNIVERSITY				
93.395	SWOG NETWORK GROUP OPERATIONS CENTER OF THE NCTN	9009627_FHCRC_RAMSEY	2014-03-01	2015-02-28	17,123
93.395	CANCER CONTROL AND PREVENTION BIOSTATISTICS CORE	1003772_FHCRC_ANDERS	2013-06-01	2015-05-31	109,046
93.395	PCPT-SELECT STATISTICAL CENTER COMBINED ACTIVITIES	1003772_FHCRC_TANGEN	2013-06-01	2015-05-31	243,820
93.395	SWOG SYMPTOM CONTROL AND QUALITY OF LIFE COMMITTEE CO-CHAIR	1003772_FHCRC_MOINPO	2013-06-01	2015-05-31	5,435
93.855	PROGRAMMING HIV IMMUNE RESPONSE FOR BROADLY NEUTRALIZING ANTIBODIES BY VACCINATION	GPRC00816A2	2013-07-01	2015-06-30	1,529
0.000	SWOG S1204: A SERO-EPIDEMIOLOGIC SURVEY AND COST-EFFECTIVENESS STUDY OF SCREENING FOR HIV, HBV AND HCV AMONG NEWLY DIAGNOSED CANCER PATIENTS	1004230_FHCRC	2013-08-01	2015-07-31	70,558
93.395	SWOG NCORP RESEARCH BASE SXQL COMMITTEE CO-CHAIR	1005019_FHCRC_MOINPO	2014-08-01	2014-12-31	6,504

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards
Year ended June 30, 2015

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period-end	Expenditures
93.395 0.000	STATISTICAL CENTER FOR SWOG NCORP RESEARCH BASE A SERO-EPIDEMIOLGIC SURVEY AND COST-EFFECTIVENESS STUDY OF SCREENING FOR HIV, HEPATITIS B AND HEPATITIS C AMONG NEWLY DIAGNOSED PATIENTS AMONG SWOG-AFFILIATED ONCOLOGY CLINICS	1005019_FH_TAN_NCORP	2014-08-01	2015-07-31	\$ 962,588
93.395	SWOG OHSU PURCHASE SERVICE AGREEMENT	1004230_FHCRC_LEBLAN	2013-08-01	2015-07-31	17,938
93.395	SWOG NETWORK GROUP OPERATIONS CENTER OF THE NCTN	SWOG MASTER PSA	2014-05-22	2020-05-21	8,049
93.395	SWOG NCORP RESEARCH BASE	9009627_FHCRC	2014-03-01	2015-02-28	4,370
93.395	NCORP: CANCER CARE DELIVERY RESEARCH PROGRAM	1005019_FHCRC_NEUHO	2014-08-01	2015-07-31	17,124
93.395	SWOG NETWORK GROUP OPERATIONS CENTER FOR THE NCTN	1005019_FH_TAN_CCDR	2014-08-01	2015-07-31	127,162
93.395	PRESAGE BIOSCIENCES	9009627_FHCRC	2015-03-01	2016-02-29	6,775
93.393	SIDEPORT NEEDLE ARRAY TECHNOLOGIES FOR PRIORITIZING DRUGS FOR CANCER PATIENTS	PRESAGE STTR IIB2012	2012-05-01	2014-08-10	10,262
93.393	PRESIDENT & FELLOWS OF HARVARD COLLEGE GENE-ENVIRONMENT EBV INTERACTIONS IN THE ETIOLOGY OF NPC PROGRAM FOR APPROPRIATE TECHNOLOGY/PATH	23570-114011	2008-09-22	2015-07-31	13,417
93.855	RECOMBINASE POLYMERASE AMPLIFICATION FOR POINT-OF-CARE DIAGNOSIS OF INFANT HIV-1	NA	2011-07-01	2015-12-31	108,196
93.283	ASSESSMENT OF THE EFFECTIVENESS OF SEASONAL TRIVALENT INFLUENZA VACCINE AMONG CHILDREN IN SENEGAL	CDC.1654-03-00481011	2014-05-01	2014-09-29	19,736
93.855	SEATTLE BIOMEDICAL RESEARCH INSTITUTE IMMUNE PROFILE AND NETWORK ANALYSIS OF MALARIA INFECTION AND VACCINATION	FH-16546-4	2013-09-01	2015-08-31	39,191
93.855	OPTIMIZING HIV IMMUNOGEN-BCR INTERACTIONS FOR VACCINE DEVELOPMENT	FH-16062-A	2014-05-01	2014-09-30	82,868
93.855	IMMUNE PROFILE AND NETWORK ANALYSIS OF MALARIA INFECTION AND VACCINATION	AWOA	2014-03-01	2014-03-02	(3,451)
93.855	IMMUNE PROFILE AND NETWORK ANALYSIS OF MALARIA INFECTION AND VACCINATION	FH-16546-4	2013-09-01	2015-08-31	74,375
93.839	SEATTLE CHILDREN'S HOSPITAL ULTRASOUND-MEDIATED GENE THERAPY FOR HEMOPHILIA B	10242SUB	2010-07-01	2014-06-30	492
93.847	SUBCLINICAL VIRAL INFECTION AND RENAL ALLOGRAFT INJURY	10339SUB	2011-07-01	2016-04-30	49,936
93.855	MULTIPLEX TEST FOR PRIMARY IMMUNODEFICIENCIES BY AFFINITY COLUMN COUPLED TO MS/MS	11124SUB	2014-09-01	2016-08-31	96,360
93.855	CORE B OF FOAMY VIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNE DEFICIENCY	10809SUB	2013-08-01	2014-07-31	39,479
93.855	CORE D OF FOAMY VIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNE DEFICIENCY	10810SUB	2013-08-01	2014-07-31	55,015
93.855	PROJECT 2 OF FOAMY VIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNE DEFICIENCY	10813SUB	2013-08-01	2014-07-31	41,372
93.113	PRENATAL ENVIRONMENTAL EXPOSURES AND REPRODUCTIVE HORMONE CONCENTRATIONS (PERCH)	11002SUB	2014-05-01	2016-04-30	10,092
93.855	VIRAL AND HOST BIOMARKERS OF HUMAN RHINOVIRUS DISEASE SEVERITY IN TRANSPLANTATION	11230SUB	2014-12-11	2015-11-30	6,091
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTION - CLINICAL CORE	10991SUB	2014-05-01	2015-04-30	36,587
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTIONS - ADMINISTRATIVE CORE	10989SUB	2014-05-01	2015-04-30	18,584
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTIONS - PROJECT 4	10990SUB	2014-05-01	2015-04-30	33,631
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTION - CLINICAL CORE	10991SUB	2014-05-01	2015-04-30	41,644
93.855	CURING HIV THROUGH ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	11112SUB	2014-09-19	2015-08-31	19,913
93.855	FOAMY VIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNE DEFICIENCY - CORE B	11094SUB	2014-08-01	2015-07-31	377,717
93.855	PROJECT 2: FOAMY VIRUS MEDIATED GENE THERAPY IN THE CANINE SCID-X1 MODEL	11164SUB	2014-08-01	2015-07-31	626,435
93.855	CORE D: VECTOR INTEGRATION AND TRACKING	11093SUB	2014-08-01	2015-07-31	218,960
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTIONS - ADMINISTRATIVE CORE	11245SUB	2015-05-01	2016-04-30	6,682
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTION - CLINICAL CORE	11244SUB	2015-05-01	2016-04-30	6,778
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTIONS - PROJECT 4	11246SUB	2015-05-01	2016-04-30	9,363
93.121	ORAL PATHOGENESIS AND HOST INTERACTIONS OF KSHV INFECTION - CLINICAL CORE	11244SUB	2015-05-01	2016-04-30	5,656
93.847	SEATTLE INST FOR BIOMEDICAL & CLIN RES EFFECT OF DIETARY GLYCEMIC INDEX ON BETA-CELL FUNCTION	UK16-FHCRC-3	2013-06-01	2014-05-31	(394)
93.847	EFFECT OF DIETARY GLYCEMIC INDEX ON BETA-CELL FUNCTION	UK16-FHCRC-4	2014-06-01	2015-05-31	212,402
93.847	EFFECT OF DIETARY GLYCEMIC INDEX ON BETA-CELL FUNCTION	AWOA	2015-06-01	2016-05-31	4,469
12.420	SLOAN-KETTERING INSTITUTE FOR CANCER RES TOWARD THE PRACTICE OF PRECISION MEDICINE: A BIOMARKER VALIDATION COORDINATING CENTER	BD516087	2013-09-30	2014-09-29	52,027
93.393	GENOME-WIDE ASSOCIATION STUDY OF RADIATION EXPOSURE AND BILATERAL BREAST CANCER	BD515757	2013-03-01	2015-02-28	2,862
93.393	MAMMOGRAPHIC DENSITY AND RISK OF CONTRALATERAL BREAST CANCER	BD516147	2013-09-01	2014-08-31	47,452
93.396	ELUCIDATING THE FUNCTION OF THE WIDELY INACTIVATED PHOSPHATASE PTPRD IN THE MOLECULAR PATHOGENESIS OF GLIOBLASTOMA	BD516975	2014-06-01	2015-05-31	18,514
93.393	MAMMOGRAPHIC DENSITY AND RISK OF CONTRALATERAL BREAST CANCER	BD517077	2014-09-01	2015-08-31	110,091
12.420	TOWARD THE PRACTICE OF PRECISION MEDICINE: A BIOMARKER VALIDATION COORDINATING CENTER	BD517299	2014-09-30	2015-09-29	200,953
93.396	ELUCIDATING THE FUNCTION OF THE WIDELY INACTIVATED PHOSPHATASE PTPRD IN THE MOLECULAR PATHOGENESIS OF GLIOBLASTOMA	ROI1CA154767	2015-06-01	2016-05-31	1,694
0.000	SOCIAL AND SCIENTIFIC SYSTEMS GENE THERAPY FOR PATIENTS WITH FANCONI ANEMIA COMPLEMENTATION GROUP A (FANCA)	CRB-SSS-S-14-003854	2014-08-04	2017-05-31	140,260
93.855	SOLIGENIX, INC BECLOMETHASONE POST EXPOSURE THERAPY FOR GASTROINTESTINAL ACUTE RADIATION SYNDROME	SUB1R43A1100417FHA	2013-07-01	2014-06-30	(18)
93.395	ST JUDE CHILDRENS RESEARCH HOSPITAL CHILDHOOD CANCER SURVIVOR STUDY	111287200-7582118	2013-12-01	2014-11-30	424,928
93.395	CHILDHOOD CANCER SURVIVOR STUDY	111287215-7631848	2014-12-01	2015-11-30	561,109
93.855	STANFORD UNIVERSITY AUTOMATED COMPARISON OF FLOW DATA FROM HIV AND VACCINE INFECTED SUBJECTS	60036089-52940-A	2012-04-06	2015-03-31	33,733
0.000	INTEGRATIVE GENOMICS FOR RISK OF CHD AND RELATED PHENOTYPES IN THE WOMEN'S HEALTH INITIATIVE	60541527-107901	2014-03-29	2015-03-28	18,951
93.393	COLON CANCER FAMILY REGISTRY COHORT	60373227-110835-1	2013-05-01	2014-04-30	(1,090)
93.393	THE COLON CANCER FAMILY REGISTRY COHORT	60373227-110835-1	2014-05-01	2015-04-30	303,490
93.393	THE COLON CANCER FAMILY REGISTRY COHORT	60373227-110835-1	2014-05-01	2015-04-30	218,092

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards
Year ended June 30, 2015

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period end	Expenditures
93.393	THE COLON CANCER FAMILY REGISTRY COHORT	60373227-110835-1	2014-05-01	2015-04-30	\$ 33,940
93.393	THE COLON CANCER FAMILY REGISTRY COHORT	60373227-110835	2015-05-01	2016-04-30	58,933
0.000	INTEGRATIVE GENOMICS FOR RISK OF CHD AND RELATED PHENOTYPES IN THE WOMEN'S HEALTH INITIATIVE	60541527-107901	2015-03-29	2016-03-28	4,319
93.393	THE COLON CANCER FAMILY REGISTRY COHORT	60373227-110835	2015-05-01	2016-04-30	40,369
	SWEDISH MEDICAL CENTER				
93.395	THE PACIFIC CANCER RESEARCH CONSORTIUM (PCRC), AND NCORP COMMUNITY SITE	907002 C.01	2014-08-01	2015-07-31	27,756
	THE CHILDREN'S HOSPITAL OF PHILADELPHIA				
93.395	STUDY CHAIR: NIH COG CHAIR GRANT	FP00013087_SUB82_01	2012-03-01	2014-12-04	(4,706)
0.000	RISK BASED THERAPY ALLOCATION IN CHILDHOOD AML: INTEGRAL STUDIES	960417RSUB_960004061	2012-03-30	2014-06-30	18,772
0.000	RISK BASED THERAPY ALLOCATION IN CHILDHOOD AML: INTEGRAL STUDIES	960417RSUB_960004061	2012-03-30	2014-06-30	(4,473)
0.000	DEVELOPMENT OF MEDICAL COUNTERMEASURES TO ENHANCE PLATELET REGENERATION AND SURVIVAL FOLLOWING RADIATION EXPOSURE FROM A RADIOLOGICAL/NUCLEAR INCIDENT	961338 - RSUB	2014-09-01	2015-08-31	163,553
93.395	COG NCTN NETWORK GROUP OPERATIONS CENTER	FP00015221_SUB529_01	2014-04-11	2016-02-29	18,388
93.395	BIQSFP: BIOMARKER, IMAGING, AND QOL STUDIES FUNDING PROGRAM - AAML1031 11XS196	961417-RSUB_95000802	2014-04-11	2015-02-28	231,183
93.395	SCIENTIFIC LEADERSHIP: COG NCTN NETWORK GROUP OPERATIONS CENTER	961212-RSUB_95000802	2014-04-11	2015-02-28	7,112
93.395	AML VICE CHAIR: COG NCTN NETWORK GROUP OPERATIONS CENTER	961329-RSUB_95000802	2014-03-01	2015-02-28	11,702
93.395	AML VICE CHAIR: COG NCTN NETWORK GROUP OPERATIONS CENTER	AWOA	2015-03-01	2016-02-29	4,850
93.395	SCIENTIFIC LEADERSHIP: COG NCTN NETWORK GROUP OPERATIONS CENTER	AWOA	2015-03-01	2016-02-29	3,464
93.395	BIQSFP: BIOMARKER, IMAGING, AND QOL STUDIES FUNDING PROGRAM	AWOA	2015-03-01	2016-02-29	100,546
	THE EMMES CORPORATION				
93.395	AIDS MALIGNANCY CLINICAL TRIALS (AMC)	PO 1568 G NA643	2013-09-01	2014-08-31	19,458
93.395	AIDS MALIGNANCY CLINICAL TRIALS (AMC)	PO 1568 G NA643	2013-09-01	2014-08-31	(1,556)
93.395	AIDS MALIGNANCY CLINICAL TRIALS (AMC)	PO 1568 G NA643	2014-09-01	2015-08-31	54,558
93.395	AIDS MALIGNANCY CLINICAL TRIALS (AMC)	PO 1568 G NA643	2014-09-01	2015-08-31	17,562
	THE GEORGE WASHINGTON UNIVERSITY				
93.395	EAST COAST AIDS AND CANCER SPECIMEN RESOURCE	12-M76	2012-09-01	2014-08-31	(118)
93.395	THE EAST COAST AIDS AND CANCER SPECIMEN RESOURCE (SUPPLEMENT)	12-M79R	2012-09-01	2015-08-31	159,930
93.395	THE EAST COAST AIDS AND CANCER SPECIMEN RESOURCE (SUPPLEMENT)	12-M79R	2012-09-01	2015-08-31	59,490
93.393	EAST COAST AIDS AND CANCER SPECIMEN RESOURCE	13-M110R	2013-09-23	2014-08-31	3,712
	THE MITRE CORPORATION				
0.000	MOLECULAR AND CELLULAR TECHNOLOGIES AND IMPLICATIONS	100996	2013-11-03	2014-11-02	35,723
	THE REGENTS OF UNIVERSITY OF MICHIGAN				
93.837	REFERENCE PROFILES OF EXRNA IN BIOFLUIDS FROM WELL DEFINED HUMAN COHORTS	3003333878	2014-08-01	2015-04-30	39,042
93.837	REFERENCE PROFILES OF EXRNA IN BIOFLUIDS FROM WELL-DEFINED HUMAN COHORTS	3003333878	2015-05-01	2016-04-30	3,387
93.837	REFERENCE PROFILES OF EXRNA IN BIOFLUIDS FROM WELL DEFINED HUMAN COHORTS	3003333878	2014-08-01	2015-04-30	37,669
93.837	REFERENCE PROFILES OF EXRNA IN BIOFLUIDS FROM WELL-DEFINED HUMAN COHORTS	3003333878	2015-05-01	2016-04-30	542
	THE SCRIPPS RESEARCH INSTITUTE				
93.855	CENTER FOR HIV/AIDS VACCINE IMMUNOLOGY AND IMMUNOGEN DISCOVERY (CHAVI-ID)	5-50828	2014-07-01	2015-06-30	55,690
	THE UNIVERSITY OF TEXAS				
93.395	TARGETING AKT SIGNALING IN AML	00910711/98010711	2012-09-01	2015-01-20	3,890
0.000	BLOOD BASED BIOMARKERS IN LUNG CANCER	00001594	2013-12-16	2014-09-24	51,968
0.000	VALIDATION OF BIOMARKERS FOR PROSTATE CANCER PROGNOSIS	00001915/PO 30003496	2014-04-09	2014-09-29	1,425
	TRUSTEES OF INDIANA UNIVERSITY, INDIANA				
0.000	RACIAL/ETHNIC DIFFERENCES IN 25(OH)D AND PTH LEVELS AND CVD AMONG WOMEN	AWOA	2013-12-01	2013-12-02	(8,406)
93.837	RACIAL/ETHNIC DIFFERENCES IN 25(OH)D AND PTH LEVELS AND CVD AMONG WOMEN	IN-4679710-FHCRC	2014-05-01	2016-04-30	97,850
	TUFTS UNIVERSITY				
93.837	CIRCULATING DIETARY AND METABOLIC FATTY ACIDS, MAJOR CVD OUTCOMES AND HEALTHY AGING	HH4023	2014-07-01	2016-06-30	151,276
	UNIV OF MIAMI - MILLER SCHOOL MEDICINE				
93.395	CIRCULATING TUMOR CELL CAPTURE AND ANALYSIS IN MULTI-CENTER PROSTATE CANCER TRIAL	660215	2013-09-05	2014-08-31	2,382
	UNIVERSITY OF ALABAMA				
93.855	UAB CENTER FOR AIDS RESEARCH: THE BIOPHYSICAL UNDERPINNINGS OF GP 120 EVOLVABILITY	000503356-SP-013-001	2014-06-01	2015-05-31	38,675
	UNIVERSITY OF ALASKA FAIRBANKS				
93.393	VALIDATING MULTIPLE STABLE ISOTOPE MEASURES OF DIET IN THE NPAAS FEEDING STUDY	UAF 14-0099/PO-FP427	2014-02-17	2016-01-31	28,521
	UNIVERSITY OF ARIZONA				
93.226	PROSPECTIVE COMPARATIVE EFFECTIVENESS TRIAL FOR MALIGNANT BOWEL OBSTRUCTION	154141	2013-09-30	2015-09-29	91,756
	UNIVERSITY OF CALIFORNIA LOS ANGELES				
93.396	INFLUENCES OF MICROENVIRONMENT ON CANCER STEM CELLS	1490 G PB453	2013-09-01	2014-08-31	38,253
93.393	INCREASING HPV VACCINE UPTAKE IN A LOW INCOME ETHNIC MINORITY POPULATION	1916 G QA044	2014-04-01	2015-03-31	16,166
93.396	INFLUENCES OF MICROENVIRONMENT ON CANCER STEM CELLS	1490 G PB453	2014-09-01	2015-08-31	176,008
93.393	INCREASING HPV VACCINE UPTAKE IN A LOW INCOME ETHNIC MINORITY POPULATION	1916 G QA044	2015-04-01	2016-03-31	10,162
93.121	SALIVARY BIOMARKERS FOR SIOGREN'S SYNDROME DETECTION-DEFINITIVE VALIDATION	1350 G PC349	2014-09-01	2015-08-31	30,607
93.121	SALIVARY BIOMARKERS FOR SIOGREN'S SYNDROME DETECTION-DEFINITIVE VALIDATION	1350 G PC349	2014-09-01	2015-08-31	76,243
	UNIVERSITY OF CALIFORNIA, SAN DIEGO				
93.113	ENDOTOXIN EXPOSURE AND RISK OF PARKINSONISM	53439468	2014-09-01	2015-08-31	69,145
	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO				
0.000	PROTOCOL 1997 - HIGH-DOSE IMMUNOSUPPRESSION AND AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE SCLEROSIS (HALT MS) STUDY	ITN10118-00sc	2007-10-01	2014-04-30	32

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards
Year ended June 30, 2015

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period-end	Expenditures
93.855	PRIMARY IMMUNE DEFICIENCY TREATMENT CONSORTIUM	7365SC	2013-09-01	2014-08-31	\$ 5,541
93.855	PRIMARY IMMUNE DEFICIENCY TREATMENT CONSORTIUM - PROJECT 4	8406SC	2014-09-01	2015-08-31	34,616
93.393	MODELING NEOPLASTIC PROGRESSION IN BARRETT'S ESOPHAGUS	8325SC	2014-08-01	2015-07-31	48,636
93.393	AIDS AND CANCER SPECIMEN RESOURCE	8291SC	2014-09-01	2015-08-31	21,440
	UNIVERSITY OF CHICAGO				
93.393	LIFESTYLE FACTORS AND LYMPHOMA: AN ASIA COHORT CONSORTIUM POOLING PROJECT	FP053223	2013-03-15	2015-02-28	29,178
93.847	METABOLICALLY ACTIVATED MACROPHAGES IN OBESITY AND INSULIN RESISTANCE	AWOA	2015-05-05	2016-04-30	12,595
	UNIVERSITY OF FLORIDA				
93.394	IMPACT OF GENETIC VARIATION ON RESPONSE TO GO THERAPY IN COG-AML CLINICAL TRIALS	UFDSP00010555	2014-07-01	2015-03-31	13,600
	UNIVERSITY OF HAWAII				
93.393	OBESITY, BODY FAT DISTRIBUTION AND CANCER RISK IN THE MULTIETHNIC COHORT	KA0100	2013-09-01	2014-08-31	151,291
93.393	OBESITY, BODY FAT DISTRIBUTION, AND CANCER RISK IN THE MULTIETHNIC COHORT	KA0100	2014-09-01	2015-08-31	547,411
	UNIVERSITY OF MARYLAND, BALTIMORE				
93.837	NHLBI PROGENITOR CELL BIOLOGY CONSORTIUM PILOT STUDY	SR00002589	2012-03-01	2014-06-30	115
93.837	INCREASING STEM CELL NUMBERS WHILE RETAINING STEM CELL FUNCTION - NHLBI PROGENITOR CELL BIOLOGY CONSORTIUM	SR00002708	2013-05-01	2014-10-31	51,940
93.837	INDUCTION OF STEM CELL EXPANSION BY THE VASCULAR NICHE-ANCILLARY PROJECT	101330A/SR0000322	2014-05-01	2016-04-30	217,165
93.837	NAIVE CAS9-HESC LINE FOR CRISPR FUNCTIONAL SCREENS-ANCILLARY PROJECT	10573	2014-08-01	2015-04-30	108,119
93.837	NHLBI PROGENITOR CELL BIOLOGY CONSORTIUM ADMINISTRATIVE COORDINATING CENTER	10560	2014-08-01	2015-04-30	220,000
93.837	NAIVE CAS9-HESC LINE FOR CRISPR FUNCTIONAL SCREENS-ANCILLARY PROJECT	101330A	2015-05-01	2016-04-30	11,620
	UNIVERSITY OF MASSACHUSETTS				
93.113	PHthalate METABOLITES AND BREAST CANCER RISK IN THE WOMEN'S HEALTH INITIATIVE	15-008747 A00	2015-04-15	2016-03-31	3,567
	UNIVERSITY OF MINNESOTA				
93.865	VIRAL IMMUNOMODULATION AND RATIONAL CMV VACCINE DESIGN	N001926102	2011-04-01	2016-01-31	134,592
93.394	IMPACT OF GENETIC VARIATION ON RESPONSE TO GO THERAPY IN COG-AML CLINICAL TRIALS	P002603502	2012-04-05	2014-06-30	(694)
93.395	PREVENTION OF BONE LOSS AFTER PEDIATRIC HEMATOPOIETIC CELL TRANSPLANTATION	N004033801	2014-09-01	2016-08-31	99,084
	UNIVERSITY OF NORTH CAROLINA CHAPEL HILL				
93.855	CAUSAL INFERENCE IN INFECTIOUS DISEASE PREVENTION STUDIES	5-30444	2009-12-01	2014-12-31	22,113
93.113	EPIGENETIC MECHANISMS OF PM-MEDIATED CVD RISK	5032973 (5-32973)	2012-08-06	2016-04-30	90,211
93.855	SYSTEMS IMMUNOGENETICS OF BIODEFENSE PATHOGENS IN THE COLLABORATIVE CROSS	5-33048	2013-08-01	2014-07-31	73,317
93.855	SYSTEMS IMMUNOGENETICS OF BIODEFENSE PATHOGENS IN THE COLLABORATIVE CROSS	5-33048	2014-08-01	2015-07-31	268,380
93.855	CAUSAL INFERENCE IN INFECTIOUS DISEASE PREVENTION STUDIES	5100949	2015-01-01	2015-12-31	33,776
	UNIVERSITY OF PENNSYLVANIA				
93.396	STEM CELLS, DIFFERENTIATION AND THERAPEUTIC RESISTANCE IN AML	556407	2011-02-10	2014-01-31	141,245
93.393	POST GWA STUDIES IN TESTICULAR GERM CELL TUMORS	561999	2013-09-18	2014-08-31	26,356
93.396	STEM CELLS, DIFFERENTIATION AND THERAPEUTIC RESISTANCE IN AML	556407-4 PO#3328218	2014-05-09	2015-01-31	138
93.398	STATISTICAL METHODS FOR THE DEVELOPMENT AND EVALUATION OF CANCER RISK PREDICTION	560862	2014-04-01	2015-03-31	46,282
93.393	POST GWA STUDIES IN TESTICULAR GERM CELL TUMORS	565489	2014-09-01	2015-08-31	144,146
93.396	STEM CELLS, DIFFERENTIATION AND THERAPEUTIC RESISTANCE IN AML	AWOA	2015-02-01	2016-01-31	39,381
93.393	STATISTICAL METHODS FOR THE DEVELOPMENT AND EVALUATION OF CANCER RISK PREDICTION	560862	2015-04-01	2016-03-31	3,734
	UNIVERSITY OF PITTSBURGH				
93.837	THE EMPHYSEMATOUS MICROENVIRONMENT PROMOTES LUNG TUMORIGENESIS AND PROGRESSION	0021343(121170-1)	2012-03-01	2015-04-30	33,671
0.000	PROPHYLAXIS VERSUS PREEMPTIVE THERAPY FOR CMV IN R-D+ LIVER TRANSPLANT RECIPIENTS	0024031-2	2011-09-26	2015-09-25	30,627
0.000	PROPHYLAXIS VERSUS PREEMPTIVE THERAPY FOR CMV IN R-D+ LIVER TRANSPLANT RECIPIENTS	0024031-2	2011-09-26	2015-09-25	65,838
	UNIVERSITY OF SOUTHERN CALIFORNIA				
93.393	FUNCTIONAL ANALYSIS OF GENOME WIDE ASSOCIATIONS IN COLORECTAL CANCER	H44554	2010-02-01	2015-01-31	4,103
93.393	TRANSDISCIPLINARY STUDIES OF GENETIC VARIATION FOR COLORECTAL CANCER	44614537	2013-07-01	2016-06-30	44,135
93.393	IMPUTATION-BASED APPROACH TO IDENTIFY LOW FREQUENCY VARIANTS IN PROSTATE CANCER	58677589	2014-09-09	2015-08-31	2,032
	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTE				
93.394	IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM: ADMIN SUPPLEMENT	155021	2013-06-30	2014-06-30	(48,043)
93.394	IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM - ADMIN SUPPLEMENT	156626	2014-07-01	2015-06-30	60,593
	UNIVERSITY OF TEXAS HSC AT SAN ANTONIO				
93.394	EDRN: DMCC CANARY PROSTATE SURVEILLANCE	155030	2013-07-01	2014-06-30	(612)
93.394	EDRN: DMCC CANARY PROSTATE SURVEILLANCE	156865	2014-07-01	2015-06-30	163,395
93.394	EDRN DMCC SCIENTIFIC WORKSHOP COORDINATION - SEPTEMBER 2014	NA - UTHSCSA	2014-07-01	2014-11-30	36,673
93.394	SABOR: BIOMARKERS AND CLINICAL PARAMETERS ASSOCIATED WITH GLEASON SCORE UPGRADING	157377	2014-07-01	2015-06-30	112,655
	UNIVERSITY OF WASHINGTON				
93.393	ACCURACY OF BREAST PATHOLOGY AND THE IMPACT OF TECHNOLOGY AND DOUBLE READING	660067	2009-07-07	2014-05-31	2,059
93.855	SEVERE CHRONIC NEUTROPENIA INTERNATIONAL REGISTRY	705277	2010-09-01	2014-08-31	4,363
93.855	DESIGN AND FUNCTION OF FLAGELLIN-BASED IMMUNOGENS FOR BROADLY NEUTRALIZING IMMUNITY TO HIV	672286	2009-09-04	2015-02-28	58,097
93.847	INTESTINAL MICROBIOTA IN DIVERTICULAR DISEASE	701877	2010-07-26	2016-06-30	92,555
0.000	GENETIC RISK FOR SMALLPOX VACCINE RELATED TO MYOCARDITIS	713535	2010-09-30	2015-06-30	119,264
93.394	MR DIFFUSION TENSOR IMAGING FOR DETECTION AND CHARACTERIZATION OF BREAST LESIONS	700336	2010-07-16	2015-05-31	19,887
93.866	DOSE-RESPONSE RELATIONSHIPS BETWEEN CIRCULATING AND INTRAPROSTATIC ANDROGENS IN MEN	721448	2011-07-01	2015-06-30	41,772
93.847	CHROMATIN RESPONSE TO ACUTE RENAL INJURY	700940	2010-08-01	2014-07-31	27,309
12.420	VACCINE TO PREVENT BREAST CANCER	731007	2011-09-30	2015-09-29	18,850
93.393	ACCURACY OF THE DIAGNOSIS OF MELANOMA AND THE IMPACT OF TECHNOLOGY AND DOUBLE READING	22724565	2011-08-01	2016-05-31	217,107

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards
Year ended June 30, 2015

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period-end	Expenditures
93.394	PANCREATIC JUICE BIOMARKER FOR PANCREATIC CANCER	726037	2011-08-01	2014-07-31	\$ 469
93.847	A TWIN STUDY OF OBESITY PATHOGENESIS USING FMRI	729356	2011-09-20	2015-08-31	16,546
93.394	ULTRASOUND ENHANCED DRUG PENETRATION FOR TREATMENT OF PANCREATIC CANCER	735227	2011-12-01	2014-08-31	12,280
93.855	INTENSE VALIDATION OF A MATHEMATICAL MODEL OF HERPES SIM	714348	2011-03-01	2015-02-28	119,440
66.509	CENTER FOR CHILD ENVIRONMENTAL HEALTH RISKS - EPA FUNDS	710279	2010-10-01	2015-08-31	120,784
66.509	CENTER FOR CHILD ENVIRONMENTAL HEALTH RISKS - EPA FUNDS	710279	2010-10-01	2015-08-31	53,492
93.242	OPTIMIZING ANTIRETROVIRAL-BASED HIV PREVENTION FOR HIV AFRICAN DISCORDANT COUPLES	724156	2011-08-10	2016-05-31	25,607
93.855	EVALUATING THE EFFECT OF PERIODIC PRESUMPTIVE TREATMENT FOR VAGINAL INFECTIONS ON THE VAGINAL MICROBIOTA: A DETAILED MOLECULAR ANALYSIS OF SAMPLES FROM A RANDOMIZED PLACEBO-CONTROLLED TRIAL.	736792	2012-02-06	2016-01-31	447,920
93.847	FEASIBILITY, EFFICACY, AND MECHANISMS OF SURGICAL VS MEDICAL DIABETES TREATMENT	715230	2010-08-18	2014-06-30	1,762
93.286	INTRACELLULAR DELIVERY OF PROAPOPTOTIC PEPTIDE DRUGS	739117	2012-04-09	2015-03-31	15,899
93.855	PREP AND PROTECTIVE IMMUNE RESPONSES AGAINST HIV-1	737619	2012-04-01	2016-03-31	416,354
93.855	PREP AND PROTECTIVE IMMUNE RESPONSES AGAINST HIV-1	737618	2012-04-01	2016-03-31	16,458
93.286	NRI SMALL: ADVANCED BIOPHOTONICS FOR IMAGE-GUIDED ROBOTIC SURGERY	745215	2012-09-01	2015-08-31	15,861
93.859	UW POST-BACCALAUREATE RESEARCH EDUCATION PROGRAM (PREP)	733206	2012-02-01	2015-04-30	6,353
93.393	DIGITAL PATHOLOGY: ACCURACY, VIEWING BEHAVIOR AND IMAGE CHARACTERIZATION	749763	2012-12-31	2015-11-30	83,164
93.855	IMMUNE MECHANISMS OF FLAVIVIRUS CONTROL: PROJECT 5	738704	2012-05-01	2013-04-30	(9)
93.855	CFAR AIDS-ASSOCIATED INFECTIONS AND MALIGNANCIES CORE	752300	2013-06-01	2014-05-31	7,653
93.855	CFAR: THE MOLECULAR PROFILING AND COMPUTATIONAL BIOLOGY CORE	752629	2013-06-01	2014-05-31	(18,310)
93.855	INTERACTION BETWEEN HSV-2 AND THE VAGINAL MICROBIOME IN THE FEMALE GENITAL TRACT	746989	2012-08-01	2014-07-31	19,124
93.847	HFMC PROSPECTIVE BIOREPOSITORY	748869	2012-06-01	2015-05-31	15,794
93.393	MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY	UWSC7371 (756757)	2013-07-01	2016-03-31	93,162
93.395	VIRAL ONCOPROTEIN TARGETED IMMUNE THERAPY FOR MERKEL CELL CARCINOMA	750685	2013-04-01	2016-03-31	194,490
93.989	AIDS INTERNATIONAL TRAINING AND RESEARCH PROGRAM, AIDS-RELATED MALIGNANCIES RESEARCH TRAINING	743714	2012-06-01	2014-05-31	3,512
93.989	AIDS INTERNATIONAL TRAINING AND RESEARCH PROGRAM, AIDS-RELATED MALIGNANCIES RESEARCH TRAINING	743714	2012-06-01	2014-05-31	(3,512)
12.420	TARGETING THE ABERRANT ANDROGEN RECEPTOR IN ADVANCED TREATMENT RESISTANT PROSTATE CANCER	757392	2013-09-30	2015-09-26	161,961
93.855	CLINICAL EPIDEMIOLOGY AND PATHOGENESIS OF ASYMPTOMATIC HSV	755563	2013-07-01	2014-06-30	2,032
93.394	PHARMACOGENETICS IN CHILDREN WITH HIGH-RISK NEUROBLASTOMA	756819	2013-09-26	2014-08-31	6,150
93.393	GENOTOXIC ESTROGEN RATIO: A NOVEL ESTROGEN BIOMARKER AND BREAST CANCER RISK	756621	2013-09-01	2016-07-31	33,615
93.395	MINIMALLY INVASIVE ABLATIVE THERAPIES IN PANCREATIC CYSTIC NEOPLASMS	753294	2013-07-01	2015-06-30	156,303
93.855	CONSERVED ELEMENTS THERAPEUTIC DNA VACCINE FOR HIV	756393	2013-08-15	2015-07-31	11,833
93.350	INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES (KL2)	755697	2013-06-01	2014-05-31	(17)
93.855	IMMUNE MECHANISMS OF FLAVIVIRUS CONTROL: PROJECT 5	751480	2013-05-01	2014-04-30	(2,932)
93.837	STEM CELLS AND CARDIOVASCULAR REPAIR - PROJECT 3	753008	2013-06-01	2014-05-31	(181)
93.135	ALLIANCE FOR REDUCING CANCER, NORTHWEST (ARC NW) [TALBOT SUBAWARD]	755388	2013-09-30	2014-09-29	15,065
93.855	IMMUNOLOGICAL AND VIROLOGICAL EVENTS IN EARLY HIV INFECTION	756159	2013-07-01	2014-06-30	(3,706)
93.989	FOGARTY GLOBAL HEALTH FELLOWSHIP - UPCID	750139	2013-03-01	2015-06-30	11,751
93.398	CANCER PREVENTION TRAINING IN NUTRITION, EXERCISE AND GENETICS	754419	2013-07-01	2014-06-30	7,044
93.853	DRUG DISCOVERY FOR THE PREVENTION OF HEARING LOSS	53179	2013-07-01	2014-06-30	(79)
93.393	HUMAN RECQ HELICASES IN BIOLOGY AND ONCOLOGY-PROJECT 5: HUMAN TUMOR ANALYSIS	754062	2013-07-01	2014-06-30	(19)
93.350	SUBAWARD FROM THE INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES	754593	2013-06-01	2014-05-31	9,460
93.350	SUBAWARD FROM THE INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES	754593	2013-06-01	2014-05-31	51,638
93.113	CENTER FOR CHILD ENVIRONMENTAL HEALTH RESEARCH	754731	2013-08-01	2014-07-31	4,131
93.855	B CELL RESPONSES AT THE FORESKIN	756723	2013-06-01	2014-05-31	(1)
93.396	PROJECT 2: TRANSMEMBRANE PROTEASES AND PROSTATE CARCINOGENESIS	753907	2013-08-01	2015-07-31	126,449
93.396	CORE A: MECHANISMS AND MARKERS OF PROSTATE CANCER METASTASES	753911	2013-08-01	2014-07-31	8,668
93.865	MALE CONTRACEPTION RESEARCH CENTER GRANT: PROJECT IV	755343	2013-07-01	2014-06-30	10
93.398	BIOBEHAVIORAL CANCER PREVENTION AND CONTROL TRAINING PROGRAM	754909	2013-08-01	2014-07-31	1,029
93.172	BIOBEHAVIORAL CANCER PREVENTION AND CONTROL TRAINING PROGRAM	754909	2013-08-01	2014-07-31	1,029
93.837	A COMPREHENSIVE CATALOG OF DNASEL HYPERSENSITIVE SITES	755703	2013-08-01	2014-07-31	39,867
93.855	STATISTICAL METHODS OF REDUCED-COST DESIGNS FOR STUDYING DISEASE AND FATALITY RISKS	UWSC7888	2014-04-15	2016-03-31	10,581
93.855	MALE URETHRITIS: NOVEL ETIOLOGIES AND NATURAL HISTORY - (MPI)	759048	2014-04-01	2016-02-29	136,747
93.855	CFAR: BLOCKING INFLAMMATION IN HIV-HCV CO-INFECTION	754957	2013-08-15	2015-05-31	11,897
93.396	DETECTION, ISOLATION AND CHARACTERIZATION OF DISSEMINATED TUMOR CELLS	753904	2013-08-01	2014-07-31	26,973
93.398	MOLECULARLY TARGETED THERAPY FOR LYMPHOMA	UWSC7938 (763550)	2014-07-18	2016-06-30	21,748
93.989	FOGARTY GLOBAL HEALTH FELLOWSHIP	752408	2013-09-01	2015-06-30	10,400
93.855	MACHINE LEARNING TO EXPAND OUR KNOWLEDGE OF APOBEC3 SPECIFICITY AND IMPROVE CLASSIFICATION OF HIV MUTATIONS	757800	2013-11-20	2014-05-31	(615)
93.855	QUANTIFYING THE IMPACT OF GENITAL MUCOSAL INFLAMMATION ON HIV-1 ACQUISITION RISK	AWOA	2015-03-01	2016-02-29	3,658
93.855	MECHANISM OF PROTECTIVE LOCAL IMMUNITY IN HUMAN FEMALE REPRODUCTIVE TRACT	758795	2014-03-05	2016-02-29	18,254
93.846	SEN PAUL D. WELLSTONE MUSCULAR DYSTROPHY COOPERATIVE RESEARCH CENTER	760632	2014-05-07	2015-04-30	40,752
93.172	A COMPREHENSIVE CATALOG OF DNASEL HYPERSENSITIVE SITES	755703	2013-08-01	2014-07-31	3,415
93.855	STATISTICAL ISSUES IN AIDS RESEARCH	759393	2014-05-01	2016-04-30	122,715
93.855	CFAR AIDS-ASSOCIATED INFECTIONS AND MALIGNANCIES CORE	752300	2013-06-01	2014-05-31	(10,413)
93.855	BIOPHYSICAL SIGNATURES IN HIV-1 ENV CORRELATING WITH MOTHER-TO-CHILD TRANSMISSION	762360	2014-07-15	2016-06-30	14,493
93.398	BIOBEHAVIORAL CANCER PREVENTION AND CONTROL TRAINING PROGRAM	754909	2013-08-01	2014-07-31	410
93.172	CLINICAL SEQUENCING IN CANCER: CLINICAL, ETHICAL, AND TECHNOLOGICAL STUDIES	756655	2013-12-01	2014-11-30	15,488

FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133

Schedule of Expenditures of Federal Awards
Year ended June 30, 2015

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period-end	Expenditures
93.847	DIABETES RESEARCH CENTER	761810	2013-12-01	2014-11-30	\$ 66,300
93.395	OPTIMIZING BUSULFAN: EFFICACY, TOXICITY, AND PHARMACOMETABOLOMICS	762390	2014-08-01	2016-07-31	83,605
93.847	DIETARY FRUCTOSE AND INTESTINAL PERMEABILITY	762000	2013-12-01	2014-11-30	8,949
47.074	THE GENETIC ARCHITECTURE OF SOMATIC MUTATION RATE	UWSC7427	2013-07-01	2015-05-31	19,009
93.855	MICROBIOME CORE: UNIVERSITY OF WASHINGTON SEXUALLY TRANSMITTED INFECTIONS COOPERATIVE RESEARCH	762698	2014-07-01	2015-06-30	727,757
93.855	PROJECT 2: UNIVERSITY OF WASHINGTON SEXUALLY TRANSMITTED INFECTIONS COOPERATIVE RESEARCH	762699	2014-07-01	2015-06-30	171,821
93.350	INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES (KL2)	762334	2014-06-01	2015-05-31	43,353
93.855	GROUPING ANTIBODY LINEAGES FROM SERIAL SEQUENCE SAMPLES	764292	2014-07-01	2015-05-31	25,000
93.855	TARGETING FNIP1 TO DISRUPT B CELL DEVELOPMENT, METABOLISM AND TRANSFORMATION	UWSC8091	2014-12-01	2015-11-30	5,081
93.839	PROEJCT 3 OF STEM CELL GENE THERAPY FOR HEMOGLOBINOPATHIES	759774	2014-04-01	2015-03-31	43,361
0.000	DEFINING A NOVEL NON-TRANSCRIPTIONAL PAT	759321	2014-01-01	2015-06-30	5,960
93.067	IMPACT OF CRYOTHERAPY VERSUS LOOP ELECTROSURGICAL EXCISION PROCEDURE (LEEP) ON HIV-1 CERVICAL SHEDDING	759227	2014-02-01	2014-07-31	41,124
93.855	CENTER FOR AIDS RESEARCH (CFAR) BIOMETRICS CORE	762865	2014-06-01	2015-05-31	85,686
93.855	CFAR AIDS-ASSOCIATED INFECTIONS AND MALIGNANCIES	764461	2014-06-01	2015-05-31	184,146
93.855	CFAR ADMINISTRATIVE CORE - CO DIRECTOR	762863	2014-06-01	2015-05-31	29,274
93.855	CENTER FOR AIDS RESEARCH (CFAR): CORE 1- IMMUNOLOGY CORE	762831	2014-06-01	2015-05-31	80,361
93.350	SUBAWARD: INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES	UWSC6680 (762142)	2014-06-01	2015-05-31	33,507
93.837	CFAR: THE MOLECULAR PROFILING AND COMPUTATIONAL BIOLOGY CORE	763023	2014-06-01	2015-05-31	256,441
93.855	CURATIVE THERAPIES FOR HIV SCIENTIFIC WORKING GROUP	762828	2014-06-01	2015-05-31	28,306
81.049	PRECLINICAL EVALUATION OF PET IMAGING FOR USE IN THE TRANSLATION OF TARGETED ALPHA THERAPY OF BLOOD-RELATED CANCERS TO CLINICAL STUDIES	764436	2014-09-01	2015-08-31	19,778
93.398	CANCER PREVENTION TRAINING IN NUTRITION, EXERCISE AND GENETICS	762379	2014-07-01	2015-06-30	37,082
93.855	IMMUNOLOGICAL AND VIROLOGICAL EVENTS IN EARLY HIV INFECTION	UWSC6263	2014-07-01	2015-06-30	42,051
93.865	MALE CONTRACEPTION RESEARCH CENTER GRANT: PROJECT IV	761943	2014-07-01	2015-06-30	23,815
93.855	IMMUNOLOGICAL AND VIROLOGICAL EVENTS IN EARLY HIV INFECTION	UWSC5834	2014-07-01	2015-06-30	70,380
93.398	BIOBEHAVIORAL CANCER PREVENTION AND CONTROL TRAINING PROGRAM	762352	2014-08-01	2015-07-31	11,371
93.859	INTERPLAY OF PROTEIN AND MEMBRANE INTERMEDIATES DURING INFLUENZA VIRUS FUSION	762324	2014-08-01	2016-03-31	20,044
93.350	SUBAWARD: INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES	UWSC6680 (762142)	2014-06-01	2015-05-31	56,358
93.350	SUBAWARD: INSTITUTE OF TRANSLATIONAL HEALTH SCIENCES	UWSC6680 (762142)	2014-06-01	2015-05-31	408,263
93.113	POLYCYCLIC AROMATIC HYDROCARBON EXPOSURE FROM URBAN AIR POLLUTION, HERPES VIRUS INFECTION AND IMMUNE FUNCTION IN UGANDAN CHILDREN	760261	2014-04-01	2015-03-31	3,130
93.173	DRUG DISCOVERY FOR THE PREVENTION OF HEARING LOSS	763167	2014-07-01	2015-06-30	31,468
93.855	CFAR AIDS-ASSOCIATED INFECTIONS AND MALIGNANCIES	764461	2014-06-01	2015-05-31	73,393
93.855	CLINICAL EPIDEMIOLOGY AND PATHOGENESIS OF ASYMPTOMATIC HSV PROJECT 1: INCIDENT HSV-2 AND GENITAL HEALTH IN KENYAN ADOLESCENT GIRLS - AN INCEPTION COHORT	762349	2014-07-01	2015-06-30	110,780
93.837	MMP28 REGULATION OF MACROPHAGE RECRUITMENT AND POLARIZATION	760477	2014-06-01	2015-05-31	8,759
93.855	MACHINE LEARNING TO EXPAND OUR KNOWLEDGE OF APOBEC3 SPECIFICITY AND IMPROVE CLASSIFICATION OF HIV MUTATION	763174	2014-06-01	2015-11-19	29,456
93.172	A COMPREHENSIVE CATALOG OF DNASE1 HYPERSENSITIVE SITES	763337	2014-08-01	2015-07-31	115,444
93.855	DEVELOPMENT AND VALIDATION OF AN HIV RISK ASSESSMENT TOOL FOR SOUTH AFRICAN WOMEN	UWSC8233	2014-12-01	2015-11-30	17,135
93.855	CHARACTERIZING TRANSMISSION OF LOW-FREQUENCY RESISTANCE VARIANTS	UWSC8282	2015-03-01	2016-05-31	2,870
93.846	SEN PAUL D. WELLSTONE MUSCULAR DYSTROPHY COOPERATIVE RESEARCH CENTER	760632	2014-05-07	2015-04-30	262,893
93.846	SEN PAUL D. WELLSTONE MUSCULAR DYSTROPHY COOPERATIVE RESEARCH CENTER	760632	2014-05-07	2015-04-30	186,505
93.398	BIOBEHAVIORAL CANCER PREVENTION AND CONTROL TRAINING PROGRAM	762352	2014-08-01	2015-07-31	11,371
93.398	BIOBEHAVIORAL CANCER PREVENTION AND CONTROL TRAINING PROGRAM	762352	2014-08-01	2015-07-31	4,224
93.855	UW STICRC: THE GENITAL MICROBIOME AS A DETERMINANT OF SEXUAL HEALTH AND LOCAL IMMUNITY	762979	2014-09-15	2015-06-30	46,847
93.855	SYSTEMS AND CARCINOGENIC IMPACT ASSESSMENT OF TOPICAL MICROBICIDES ON HUMAN MUCOSA	UWSC8463	2015-05-01	2016-04-30	26,217
93.847	DIABETES RESEARCH CENTER	UWSC7039	2014-12-01	2015-11-30	95,240
93.837	INNOVATIVE MULTIGENERATIONAL HOUSEHOLD INTERVENTION TO REDUCE STROKE AND CVD	764077	2014-05-05	2015-04-30	10,438
93.399	CENTER FOR NATIVE POPULATION HEALTH DISPARITIES (CINCO)	764174	2014-05-01	2015-04-30	8,090
93.310	CONTINGENCY MANAGEMENT TREATMENT OF ALCOHOL ABUSE AMERICAN INDIAN PEOPLE	UWSC8136	2014-09-01	2015-08-31	6,071
93.866	NATIVE ELDER RESEARCH CENTER (NERC)	UWSC8081	2014-08-15	2015-06-30	8,100
93.837	TRIBAL HEALTH AND RESILIENCE IN VULNERABLE ENVIRONMENTS STUDY	UWSC8083	2014-06-01	2016-03-31	9,106
93.837	STRONG HEART STROKE STUDY	UWSC8137	2014-07-01	2015-06-30	17,777
12.420	THE FANCONI ANEMIA BRCA PATHWAY AS A PREDICTOR OF BENEFIT FROM BEVACIZUMAB IN A LARGE PHASE III CLINIC TRIAL IN OVARIAN CANCER	762023	2014-09-30	2015-09-29	15,140
93.393	CLINICAL SEQUENCING IN CANCER: CLINICAL ETHICAL AND TECHNOLOGICAL STUDIES	764391	2014-12-01	2015-11-30	22,523
93.855	MECHANISMS OF FORMATION AND PERSISTENCE OF ACTIVE HIV RESERVOIRS	AWOA	2014-10-01	2015-02-28	11,310
93.837	STEM CELLS AND CARDIOVASCULAR REPAIR: IMPACT OF CIGARETTE SMOKE ON MYOCARDIAL REMODELING	764043	2014-08-15	2015-05-31	3,743
93.397	REGIONAL NATIVE AMERICAN COMMUNITY NETWORKS PROGRAM (NPCC)	764416	2014-09-01	2015-08-31	6,087
	CENTER FOR AIDS RESEARCH (CFAR) BIOMETRICS CORE	AWOA	2015-06-01	2016-05-31	8,322
93.067	IMPACT OF CRYOTHERAPY VS LOOP ELECTROSURGICAL EXCISION PROCEDURE (LEEP) ON HIV-1 CERVICAL SHEDDING	UWSC8227	2015-02-01	2015-07-31	81,024
	CFAR: CURATIVE THERAPIES FOR HIV SCIENTIFIC WORKING GROUP	AWOA	2015-06-01	2016-05-31	1,456
93.855	CFAR AIDS-ASSOCIATED INFECTIONS AND MALIGNANCIES CORE	AWOA	2015-06-01	2016-05-31	11,888
	CFAR ADMINISTRATIVE CORE: CO-DIRECTOR	AWOA	2015-06-01	2016-05-31	3,049
93.855	CFAR: MOLECULAR PROFILING AND COMPUTATIONAL CORE	AWOA	2015-06-01	2016-05-31	20,046
93.855	CENTER FOR AIDS RESEARCH (CFAR): CORE 1- IMMUNOLOGY CORE	762831	2014-06-01	2015-05-31	52,026
93.846	SEN PAUL D. WELLSTONE MUSCULAR DYSTROPHY COOPERATIVE RESEARCH CENTER	AWOA	2015-05-01	2016-04-30	36,273
93.846	SEN PAUL D. WELLSTONE MUSCULAR DYSTROPHY COOPERATIVE RESEARCH CENTER	AWOA	2015-05-01	2016-04-30	26,832

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Expenditures of Federal Awards
Year ended June 30, 2015

Federal CFDA or grant	Federal grant/pass-through grantor/program title	Pass-through entity or award identifying number	Award period begin	Award period- end	Expenditures
93.135	CENTER FOR AIDS RESEARCH (CFAR): CORE 1 - IMMUNOLOGY CORE	AWOA	2015-06-01	2016-05-31	\$ 5,817
93.866	LONG-TERM FOLLOW-UP OF THE FAMILY AND CANCER THERAPY SELECTION (FACTS) STUDY PARTICIPANTS	755396	2013-09-30	2014-09-29	(1,214)
93.846	NATHAN SHOCK CENTER STORAGE OF NLTC3 BIOSPECIMENS	763088	2014-08-15	2015-06-30	30,013
	SEN PAUL D. WELLSTONE MUSCULAR DYSTROPHY COOPERATIVE RESEARCH CENTER	AWOA	2015-05-01	2016-04-30	9,146
93.837	UNIVERSITY OF WISCONSIN				
	GENETIC VARIANTS ASSOCIATED WITH CVD RISK AND HORMONE THERAPY INTERACTIONS	153405507	2014-07-15	2015-06-30	69,366
	VAN ANDEL RESEARCH INSTITUTE				
93.394	TARGETED GLYCOMICS AND AFFINITY REAGENTS FOR CANCER BIOMARKER DEVELOPMENT	BH-10-40234-01	2013-07-01	2014-06-30	(190)
93.394	TARGETED GLYCOMICS AND AFFINITY REAGENTS FOR CANCER BIOMARKER DEVELOPMENT	FHCRC-BH-10-40234-1	2014-07-01	2015-06-30	13,215
93.393	VANDERBILT UNIVERSITY MEDICAL CENTER				
	CANCER MORTALITY AMONG MILITARY PARTICIPANTS AT US NUCLEAR WEAPONS TESTS	VUMC 37160	2014-07-01	2015-06-30	27,533
93.393	WAKE FOREST UNIVERSITY HEALTH SCIENCES				
	GENE-HORMONE THERAPY INTERACTION AND THE RISK OF BREAST CANCER	10633	2011-03-01	2015-02-28	5,373
93.847	WASHINGTON UNIVERSITY IN SAINT LOUIS				
	GENETIC ARCHITECTURE OF ADIPOSITY IN MULTIPLE LARGE COHORTS	WU-15-111	2014-09-19	2015-06-30	21,045
93.837	A MULTI-ETHNIC STUDY OF GENE-LIFESTYLE INTERACTIONS IN CARDIOVASCULAR TRAITS	PO2922895Y WU-15-269	2015-01-01	2015-12-31	4,482
	Total - Pass-Through Funds				<u>30,371,583</u>
	TOTAL RESEARCH AND DEVELOPMENT				<u>276,714,271</u>
	OTHER AWARDS				
98.006	USAID FOREIGN ASSISTANCE TO AMERICAN SCHOOLS AND HOSPITALS ABROAD				259,839
	Total Schedule of Expenditures of Federal Awards				\$ <u>276,974,110</u>

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2015

(1) Basis of Presentation

The accompanying schedule of expenditures of federal awards (SEFA) includes the federal grant activity of Fred Hutchinson Cancer Research Center and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of OMB Circular A-133, *Audits of States, Local Governments, and Non-Profit Organizations*. Therefore, some amounts presented in this schedule may differ from amounts presented in, or used in the preparation of, the financial statements.

(2) Subrecipients

Of the federal expenditures presented in the Schedule of Federal Expenditures of Federal Awards, Fred Hutchinson Cancer Research Center provided federal awards to subrecipients as follows:

<u>Award Title</u>	<u>CFDA number</u>	<u>Expense amount</u>
A COHORT STUDY OF SESSILE SERRATED POLYPS AND SUBSEQUENT COLORECTAL NEOPLASIA	93.393	\$ 493,268
A MULTI-STATE STUDY OF CANCER TREATMENT AND OUTCOME AMONG AMERICAN INDIANS	93.393	44,178
A RANDOMIZED PHASE II TRIAL OF CMV PREVENTION IN ACUTE LUNG INJURY	93.838	487,859
ACCEPTANCE AND COMMITMENT THERAPY FOR SMOKING CESSATION	93.393	81,125
ADVANCED DEVELOPMENT OF IMMUNO-MRM TECHNOLOGY TO ANALYZE ARCHIVED CANCER TISSUES	93.394	48,678
AFFINITY BASED STRATEGIES TO FAST TRACK DEVELOPMENT OF COLON CANCER BIOMARKERS	93.394	51,344
AIDS MALIGNANCY CLINICAL TRIALS (AMC)	93.395	10,217
ALPHA EMITTER LABELED ANTI-T CELL ANTIBODY: TARGETING LATENT HIV INFECTED CELLS	93.855	14,903
ALPHA RADIOIMMUNOTHERAPY FOR LYMPHOMA TREATMENT	93.395	124,521
AN INTEGRATED COMPUTATIONAL AND FUNCTIONAL GENOMICS DISCOVERY ENGINE FOR PRE-CLINICALLY VALIDATED CANCER DRUG TARGETS	93.394	125,513
BARRETT'S ESOPHAGUS: PREDICTOR'S OF PROGRESSION	93.394	77,553
BIGDATA: MID-SCALE: DA: ESCE: COLLABORATIVE RESEARCH: SCALABLE STATISTICAL COMPUTING FOR EMERGING OMICS DATA STREAMS	47.070	408,170
BIOCONDUCTOR: AN OPEN COMPUTING RESOURCE FOR GENOMICS	93.172	212,153

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2015

Award Title	CFDA number	Expense amount
BIOLOGIC DETERMINANTS OF THE NATURAL HISTORY OF AIDS-DEFINING CANCERS IN UGANDA	93.397	\$ 52,399
BIOLOGY AND PROGNOSTIC IMPLICATIONS OF FLT3 MUTATIONS IN AML	93.394	38,459
BIOMARKER DISCOVERY FOR MITOCHONDRIAL TOXICANTS USING METABOLIC FOOTPRINTING	93.113	32,587
BIOMARKERS FOR EARLY DETECTION OF CLINICALLY RELEVANT PROSTATE CANCER: A MULTI-INSTITUTIONAL VALIDATION TRIAL	12.420	202,990
BISPECIFIC ANTIBODY ENGINEERING FOR AML RIT	93.395	6,152
BMT CTN 1101 ANCILLARY COST-EFFECTIVENESS ANALYSIS	93.839	8,584
BREAST AND OVARY CANCER CLINICAL VALIDATION CENTER	93.394	50,047
CANCER CENTER SUPPORT GRANT	93.397	228,552
CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)	93.397	1,234,426
CANCER GENOMICS: INTEGRATIVE AND SCALABLE SOLUTIONS IN R/BIOCONDUCTOR	93.393	131,333
CANCER IMMUNOTHERAPY TRIALS NETWORK CENTRAL OPERATIONS AND STATISTICAL CENTER	93.395	1,399,615
CD38 PRETARGETED RADIOIMMUNOTHERAPY FOR MYELOMA	93.395	68,180
CENTER FOR HISPANIC HEALTH PROMOTION: REDUCING CANCER DISPARITIES	93.397	31,425
CENTER FOR STATISTICS AND QUANTITATIVE INFECTIOUS DISEASES	93.859	341,259
CHARACTERIZATION OF (HIV)-1 ANTIBODY RESPONSES IN CHRONICALLY INFECTED WOMEN	93.855	141,649
CHEMOPROTECTION AGAINST AMINOGLYCOSIDE-INDUCED OTOTOXICITY	93.173	6,840
CLINICAL COORDINATING CENTER FOR THE WOMEN'S HEALTH INITIATIVE 2010-2015 EXTENSION	0.00	2,478,743
CLINICAL SIGNIFICANCE OF MAJOR HISTOCOMPATIBILITY (MHC) HAPLOTYPES IN HEMATOPOIETIC CELL TRANSPLANTATION (HCT)	93.395	2,473
COLLABORATION FOR A HEALTHY COMMUNITY	93.307	60,603
COLORECTAL TUMOR RISK PREDICTION IN THE PLCO TRIAL	93.394	29,124
CONTAINING BIOTERRORISM AND EMERGING INFECTIOUS DISEASES	93.859	159,010
CORE CENTER OF EXCELLENCE IN HEMATOLOGY	93.847	5,903
CORRELATING TCR DIVERSITY TO IMMUNE RECONSTITUTION AFTER CORD BLOOD TRANSPLANT	93.839	21,064

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2015

Award Title	CFDA number	Expense amount
CYTOTOXIC T-CELL REPOSES TO HSV IN HIV-INFECTED PERSONS	93.855	\$ 218,141
DEEP SEQUENCING FOR MINIMAL RESIDUAL DISEASE DETECTION IN ACUTE LYMPHOBLASTIC LEUKEMIA	93.394	82,407
DEFINING BCR EVOLUTION DURING IMMUNIZATION DETECTION OF COLORECTAL CANCER SUSCEPTIBLY	93.855	168,989
LOCI USING GENOME-WIDE SEQUENCING	93.393	3,857,078
DEVELOPING UBIQUITIN LIGASE AGONISTS AS CANCER THERAPEUTICS	93.395	294,639
DEVELOPMENT AND VALIDATION OF AN HIV RISK ASSESSMENT TOOL FOR AFRICAN WOMEN	93.242	2,142
DEVELOPMENT OF A COMPREHENSIVE MODEL FOR COLORECTAL CANCER RISK PREDICTION	93.393	232,976
DEVELOPMENT OF NOVEL AIDS GENE THERAPY STRATEGIES IN THE MACAQUE SHIV MODEL	93.855	71,134
DEVELOPMENT OF SAFE AND EFFICIENT GENE THERAPY STRATEGIES FOR HEMOGLOBINOPATHIES	93.839	77,787
DEVELOPMENT OF A CERVICAL CANCER SCREENING PROGRAM FOR REFUGEE WOMEN	93.393	7,567
DIETARY FRUCTOSE AND LOW-GRADE INFLAMMATION DISCOVERY AND OPTIMIZATION OF AML	93.837	1,215
PROGNOSTIC BIOMARKERS	93.394	27,538
DYNAMICS OF GRADIENT SENSING IN SINGLE CELLS	93.859	22,000
EARLY AND REINFECTION IN HIGH RISK WOMEN	93.855	231,739
EARLY DETECTION RESEARCH NETWORK: DATA MANAGEMENT AND COORDINATING CENTER	93.394	173,634
ELICITING VRC01-LIKE BNABS BY SPECIFICALLY DESIGNED ENV IMMUNOGENS	93.855	449,723
EPIDEMIOLOGIC FACTORS AND SURVIVAL BY MOLECULAR SUBTYPES OF OVARIAN CANCER	93.393	318,337
EPIDEMIOLOGY OF PUTATIVE GENETIC GENETIC VARIANTS IN THE WOMEN'S HEALTH INITIATIVE	93.172	40,974
EPIGENOMIC PROFILING OF HISTONE TURNOVER KINETICS IN MAMMALIAN CELLS	93.113	43,797
ESOPHAGEAL CANCER FROM CELLS TO POPULATION: A MULTISCALE APPROACH	93.393	314,677
EVALUATION OF A HEPATITIS B OUTREACH INTERVENTION FOR CAMBODIANS	93.393	29,217
EVALUATION OF PLURIPOTENT STEM CELL-DERIVED BLOOD CELLS IN NONHUMAN PRIMATE MODEL	93.839	287,070
EVOLUTION OF CANCER-SPECIFIC MOLECULAR REQUIREMENTS FOR GLIOBLASTOMA MULTIFORME (PQ8)	93.396	9,663

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2015

Award Title	CFDA number	Expense amount
EXONIC VARIANTS AND THEIR RELATION TO COMPLEX TRAITS IN MINORITIES OF THE WHI	93.172	\$ 17,947
EXPANDING CAPACITY FOR INFECTION-RELATED CANCER RESEARCH BY EXAMINING THE CONTRIBUTION OF VIRAL GENOMIC DIVERSITY TO THE CLINICAL MANIFESTATIONS OF CANCER IN UGANDA	0.00	43,600
EXPANSION OF CARDIAC AND HEMATOPOIETIC PROGENITORS BY WNT AND NOTCH (MPI)	93.837	399,834
FFPE VALIDATION OF A SURVIVAL GENE SIGNATURE IN HPV-NEGATIVE ORAL CAVITY CANCER	93.394	3,114
FUNCTIONAL METHODS FOR RADIATION EXPOSURE AND BIOMARKER DATA	93.113	18,535
GENETIC MECHANISMS OF SURVIVORSHIP DISPARITIES AFTER UNRELATED HCT	93.393	15,480
GUT MICROBIOTA AND COLONIC GENE EXPRESSION: A LIGNAN TRIAL IN HUMANS	93.393	100,626
HEMATOPOIETIC CHIMERISM AFTER STEM CELL ALLOGRAFTS	93.395	83,386
HEMATOPOIETIC STEM CELL AND CORD BLOOD TRANSPLANTATION	93.855	441,229
HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMISSION AMONG HIGH-RISK MSM	93.279	1,520,873
HPV CAPSID ANTIBODIES	93.855	9,351
HUMAN IMMUNOLOGY PROJECT CONSORTIUM DATABASE HIPC-DB_RESEARCH PORTAL	0.00	22,773
HUTCHINSON CENTER AS LEAD ACADEMIC PARTICIPATING SITE (U10)	93.395	110,758
IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM	93.394	228,952
IDENTIFY AND VALIDATE NOVEL EPIGENETIC MOLECULAR MARKERS FOR COLORECTAL NEOPLASM - ADMIN SUPPLEMENT	93.394	32,728
IMMUNE MEDIATED DISORDERS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS (HCT)	93.855	521,453
IMPROVING OUTCOMES ASSESSMENT IN CHRONIC GRAFT VERSUS HOST DISEASE	93.395	256,591
IN VIVO EFFECTS OF SULFORAPHANE SUPPLEMENTATION ON NORMAL HUMAN PROSTATE	93.393	90,012
INTERGRATED SENSOR TECHNOLOGY FOR REAL-TIME RECORDING OF FOOD INTAKE	93.393	49,814

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2015

Award Title	CFDA number	Expense amount
INTERNET STUDIES TO ENHANCE LONG TERM SURVIVORSHIP AFTER HEMATOLOGIC MALIGNANCY	93.395	\$ 148,298
LATE EFFECTS OF TREATMENT IN WILMS TUMOR SURVIVORS AND OFFSPRING	93.393	24,607
LC: HIV VACCINE TRIALS NETWORK	93.855	5,145,732
LEUKOCYTE TELOMERE LENGTH AND CARDIOVASCULAR DISEASE IN JACKSON HEART STUDY	93.837	593,963
LEVERAGING DEEP SEQUENCING DATA TO UNDERSTAND ANTIBODY MATURATION	93.859	20,005
LOC: HIV VACCINE TRIALS NETWORK	93.855	8,382,552
LONG-TERM FOLLOW-UP OF THE FAMILY AND CANCER THERAPY SELECTION (FACTS) STUDY PARTICIPANTS	0.00	14,738
LOOKING BEYOND CYP17A: EXPLOITING PRERECEPTOR REGULATION TO OPTIMIZE NEXT-GENERATION STEROID-SYNTHESIS INHIBITION IN CASTRATION-RESISTANT PROSTATE CANCER	12.420	18,648
MECHANISMS AND COFACTORS OF HIV TRANSMISSION TO WOMEN	93.865	688,692
MECHANISMS OF EUKARYOTIC TRANSCRIPTION ACTIVATION	93.859	71,298
MENOPAUSAL SYMPTOMS INITIATIVE-FINDING LASTING ANSWERS FOR SWEATS AND HOT FLASHES	93.866	340,918
METABOLITE BIOMARKERS IN THE DEVELOPMENT OF ESOPHAGEAL ADENOCARCINOMA	93.394	147,892
METHODS FOR EVALUATING VACCINE EFFICACY	93.855	169,544
METHODS FOR MEASUREMENT ERROR IN PHYSICAL ACTIVITY AND DIET DATA	93.837	28,996
METHODS FOR TIME-VARYING DISEASE ATTRIBUTION IN CHRONIC DISEASE PREVENTION	93.393	40,035
MODELING PROSTATE CANCER CONTROL: PREVENTION, SCREENING, TREATMENT, FOLLOWUP CARE	93.393	522,506
MOLECULAR CORRELATES OF OUTCOMES IN CLINICAL TRIALS OF COLON CANCER	93.393	126,388
MOLECULAR PATHOLOGICAL EPIDEMIOLOGY OF COLORECTAL CANCER	93.393	201,954
MRM-BASED QUANTIFICATION OF PROTEINS AND PHOSHOPEPTIDES IN THE RAS SIGNALING PATHWAY	0.00	17,983
NCORP: CANCER CARE DELIVERY RESEARCH PROGRAM	93.395	36,787
NON INVASIVE BIOMARKERS FOR DIAGNOSING CLINICALLY SIGNIFICANT PROSTATE CANCER	93.394	87,755
NOTCH-MEDIATED EXPANSION OF CORD BLOOD PROGENITORS FOR STEM CELL TRANSPLANT	93.837	147,624

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2015

Award Title	CFDA number	Expense amount
NOVEL PATHOGEN ASSOCIATED CANCERS (PQ12)	93.393	\$ 228,274
NUTRITION AND PHYSICAL ACTIVITY ASSESSMENT STUDY (NPAAS)	93.393	90,942
OBJECTIVE PHYSICAL ACTIVITY AND CARDIOVASCULAR HEALTH IN WOMEN AGED 80 AND OLDER	93.837	520,801
OPTIMIZING HIV IMMUNOGEN-BCR INTERACTIONS FOR VACCINE DEVELOPMENT	93.855	148,092
OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER	93.395	6,987
P31K SIGNALING AND BIOLOGY OF THERAPEUTIC RESPONSE IN BRAIN AND PROSTATE TUMORS	93.396	289,113
PACIFIC OVARIAN CANCER RESEARCH CONSORTIUM PCPT AND SELECT COHORTS: CORE INFRASTRUCTURE	93.397	226,655
SUPPORT FOR CANCER RESEARCH	93.394	369,916
PERIPHERAL BLOOD BIOPSY FOR MOLECULAR DIAGNOSIS OF PANCREATIC CANCER	93.394	8,074
PRECLINICAL GENE THERAPY STUDIES IN CANINE MUSCULAR DYSTROPHY	93.846	6,327
PREDICTION OF TREATMENT-RELATED MORTALITY AND THERAPEUTIC RESISTANCE IN AML	93.393	9,021
PREGNANCY OUTCOMES IN WOMEN WITH DISABILITIES: EXPLORATORY RESEARCH	93.865	34,127
PREP EXPOSURE DURING HIV-1 INFECTION AND THE RISK OF LOW-FREQUENCY ARV RESISTANCE	93.855	19,957
PRETARGETED RADIOIMMUNOTHERAPY OF CD20+ LYMPHOMAS	93.395	53,705
PROFILING CANCER NEOANTIGEN REPERTOIRES AND VALIDATING IMMUNOTHERAPY TARGETS	93.394	60,257
PROMISS: PROSTATE MODELING TO IDENTIFY SURVEILLANCE STRATEGIES	93.393	242,187
PROSPECTIVE COMPARATIVE EFFECTIVENESS TRIAL FOR MALIGNANT BOWEL OBSTRUCTION	93.226	26,021
PROSPR: STATISTICAL COORDINATING CENTER (PSCC)	93.393	103,136
RANDOMIZED TRIAL OF WEB-DELIVERED ACCEPTANCE THERAPY FOR SMOKING CESSATION	93.393	64,681
REGULATION OF CELL MIGRATION AND SIGNALING BY PHOSPHOTYROSINE AND UBIQUITIN	93.859	7,314
ROLE OF THE PERIVASCULAR MICROENVIRONMENT IN PRIMARY AND METASTATIC BRAIN TUMORS	93.397	744,533
SDMC: HIV PREVENTION TRIALS NETWORK	93.855	547,584
SDMC: MICROBICIDE TRIALS NETWORK	93.855	229,250

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2015

Award Title	CFDA number	Expense amount
SEATTLE CANCER CONSORTIUM BREAST SPORE (SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE)	93.397	\$ 305,241
SEATTLE-LAUSANNE-KAMPALA CTU	93.855	1,090,583
SINGLE-CELL METHODS FOR ANALYSIS OF CLONAL HETEROGENEITY AND EVOLUTION IN CANCER	93.394	222,608
SMCHD1 PATHWAYS AS CANDIDATE TARGETS FOR FSHD	93.846	171,968
STATINS FOR PREVENTION OF GVHD	93.839	1,000
STATISTICAL CENTER FOR SWOG NCORP RESEARCH BASE BASE	93.395	535,218
STATISTICAL METHODS FOR COMBINATION HIV PREVENTION APPROACHES	93.242	8,953
STATISTICAL METHODS FOR MEDICAL STUDIES	93.393	59,009
STATISTICAL METHODS FOR PROSPECTIVE EVALUATION OF BIOMARKERS	93.859	77,763
STATISTICAL METHODS FOR SELECTION AND EVALUATION OF BIOMARKERS	93.859	15,572
STATISTICAL METHODS IN HIV VACCINE EFFICACY TRIALS	93.855	127,070
STEROID TRANSPORT PROTEINS IN CASTRATION- RESISTANT PROSTATE CANCER	12.420	1,671
STRATEGIES TO IMPROVE THE ADOPTIVE TRANSFER OF T CELLS	93.396	51,448
SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) PROGRAM	0.00	68,631
SWOG STATISTICS AND DATA MANAGEMENT CENTER	93.395	4,144,920
T CELL IMMUNITY TO HSV-2 IN IMMUNE SERONEGATIVE SUBJECTS	93.855	319,157
TARGETED INTERVENTION FOR BIPOLAR SMOKERS	93.279	6,671
TARGETED MODIFICATION OF HOST AND PROVIRAL DNA TO TREAT LATENT HIV INFECTION	93.855	3,453,448
TARGETED RADIOTHERAPY WITH 90Y-BC8 MONOCLONAL ANTIBODY, FLUDARABINE AND TBI FOLLOWED BY HLA-MATCHED, ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANT FOR THE TREATMENT OF MULTIPLE MYELOMA	93.395	97,516
TARGETED THERAPY OF ALL WITH GENE-MODIFIED CENTRAL MEMORY T CELLS	93.395	10,447
TARGETED THERAPY OF B CELL MALIGNANCIES WITH CAR-T CELLS OF DEFINED COMPOSITION	93.395	163,993
TELOMERES AND LUNG CANCER INCIDENCE AND SURVIVAL	93.393	151,250

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Notes to Schedule of Expenditures of Federal Awards

June 30, 2015

Award Title	CFDA number	Expense amount
TELOMERES DYNAMICS, CARDIOVASCULAR RISK, AND LONGEVITY IN OLDER WOMEN	0.00	\$ 376,568
THE GENETICS OF PARALLEL REPRODUCTIVE ISOLATION IN STICKLEBACK SPECIES PAIRS	93.859	36,606
THE HIPPO PATHWAY IN PROSTATE GLAND HOMEOSTASIS AND PROSTATE CANCER	93.396	21,876
THE PACIFIC NORTHWEST PROSTATE CANCER SPECIALIZED PROGRAM OF RESEARCH EXCELLENCE (SPORE)	93.397	930,940
THE PATHOGENESIS OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY	93.853	395,802
THE ROLE OF ANTIBODIES IN MOTHER TO CHILD HIV TRANSMISSION	93.855	53,827
THE ROLE OF UNCULTIVATED BACTERIA IN BACTERIAL VAGINOSIS	93.855	321,271
THE STATISTICAL AND COMPUTATIONAL ANALYSIS OF FLOW CYTOMETRY DATA	93.286	91,821
THERAPY OF LYMPHOMA/LEUKEMIA WITH MONOCLONAL ANTIBODIES	93.395	366,447
TILLING THE ZEBRAFISH GENOME: A REVERSE GENETICS APPROACH	93.172	265,386
TRANSLATIONAL STUDIES OF INHERITED MARROW FAILURE AND MYELODYSPLASTIC SYNDROMES	93.847	1,687,168
TREC COORDINATION CENTER	93.394	88,498
UNDERSTANDING AND PREVENTING BREAST CANCER DISPARITIES IN LATINAS	93.399	508,284
USING MEDICAL INFORMATICS TO FOLLOW-UP A COLORECTAL SESSILE SERRATED POLYP COHORT	93.393	7,214
USING MOUSE MODELS TO PROBE THE RELATIONSHIP OF ONCOGENESIS TO DEVELOPMENT AND ONCOGENIC MUTATIONS	93.396	55,623
WEIGHT LOSS AND CANCER BIOMARKERS IN WOMEN: OXIDATIVE STRESS AND INFLAMMATION	93.393	119,297
WHOLE GENOME ASSOCIATION ANALYSIS OF HEMATOPOIETIC CELL TRANSPLANT (HCT) OUTCOME	93.839	130,883
WOMEN'S HEALTH INITIATIVE CANCER SURVIVOR COHORT	93.393	593,246
		<u>\$ 57,989,162</u>

**FRED HUTCHINSON CANCER RESEARCH CENTER
OMB CIRCULAR A-133**

Schedule of Findings and Questioned Costs

June 30, 2015

(1) Summary of Auditors' Results

Financial Statements

Type of auditors' report issued: **Unmodified**

Internal control over financial reporting:

- Material weakness(es) identified: **No**
- Significant deficiency(ies) identified that are not considered to be material weaknesses: **No**

Noncompliance material to financial statements noted: **No**

Federal Awards

Internal control over major programs:

- Material weakness(es) identified: **No**
- Significant deficiency(ies) identified that are not considered to be material weaknesses: **No**

Type of auditors' report issued on compliance for major programs: **Unmodified**

Any audit findings disclosed that are required to be reported in accordance with Section 510(a) of OMB Circular A-133: **No**

Identification of major program:

Federal grantor and program title	CFDA number
Research and Development Cluster	Various

Dollar threshold used to distinguish between type A and type B programs: **\$3,000,000**

Auditee qualified as low-risk auditee: **Yes**

(2) Financial Statement Findings

None.

(3) Federal Award Findings and Questioned Costs

No findings.